Binder compositions and uses thereof

Information

  • Patent Grant
  • 12351738
  • Patent Number
    12,351,738
  • Date Filed
    Monday, October 11, 2021
    3 years ago
  • Date Issued
    Tuesday, July 8, 2025
    13 days ago
Abstract
The present invention relates to new aqueous binder compositions comprising an aqueous curable binder composition comprising starting materials required for forming a thermoset resin upon curing and a matrix polymer, wherein the starting materials required for forming a thermoset resin upon curing comprise (i) a polyhydroxy component and a polycarboxylic acid component, or an anhydride, ester or salt derivative thereof and/or reaction product thereof, or (ii) a carbohydrate component and a nitrogen containing component and/or a reaction product thereof.
Description
TECHNICAL FIELD AND SUMMARY

The present invention relates to new improved binder compositions, more specifically curable binder compositions for use in manufacturing products from a collection of non or loosely assembled matter. For example, these binder compositions may be employed to fabricate fiber products which may be made from woven or nonwoven fibers. In one illustrative embodiment, the binder compositions are used to bind glass fibers to make fiberglass. In another illustrative embodiment, the binder compositions are used to bind mineral wool fibers, such as glass wool or stone wool in a matted layer, such as an insulating product. In a further embodiment, the binders are used to make cellulosic compositions. With respect to cellulosic compositions, the binders may be used to bind cellulosic matter to fabricate, for example, wood fiber board or particle board which has desirable physical properties (e.g., mechanical strength). The invention further extends to a product made from loosely assembled matter bound by a binder of the invention.


BACKGROUND

Several formaldehyde-free binder compositions have been developed in recent times. One such curable binder composition involves sustainable materials and is based on polyester chemistry, more particularly curable aqueous binder compositions comprising a polyacid component or anhydride or salt derivatives thereof, and a polyhydroxy component, possibly together with a silicon containing compound. Another such composition involves the condensation of ammonium salt of inorganic acids or of polycarboxylic acids or an amine, preferably a polyamine, with reducing sugars as thermosets. These chemistries show advantages as compared to prior formaldehyde based technology, but also show certain weaknesses, and there still is a need for improved binder chemistry. Some of the known binder chemistries show a relatively high binder weight loss upon exposure to heat. Some also show undesirable degradation in humid environments which may negatively affect the bond strength properties of the products containing same. There further is an ongoing interest in improving the bond strength of the employed binder compositions, hence providing improved final products, showing improved properties, and/or final products with reduced binder content, at more advantageous costs.


OBJECTS OF THE INVENTION

The present invention seeks to provide binders which generate or promote cohesion and are capable of holding a collection of matter together such that the matter adheres in a manner to resist separation. An objective of the present invention is to provide binders showing improved bond strength, as compared to close prior art binder compositions, more particularly such binder compositions based on polyester chemistry or the condensation of ammonium salt of inorganic acid or ammonium salt of polycarboxylic acids or amine with reducing sugars as thermosets.


Another objective of the present invention is to provide cost-effective binder compositions for large volume applications.


Another objective is to provide a binder composition based on renewable and/or sustainable resources.


Further, the invention seeks to provide binder compositions that rapidly cure into strong binders.


Yet another purpose of the invention is to provide an assembly of matter bonded with the invention binder.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1-3 show the cure rate of several binder compositions;



FIG. 4 shows the bond strength before and after weathering for dextrose/ammonium sulphate/polymer based binder compositions:



FIG. 4a—dextrose/ammonium sulphate/chitosan (Mw60 kDa-220 kDa),



FIG. 4b—dextrose/ammonium sulphate/partially hydrolysed PVA (Mw30 kDa-70 kDa),



FIG. 4c—dextrose/ammonium sulphate/carboxymethyl cellulose (Mw˜250 kDa);



FIG. 5 shows the bond strength before and after weathering for dextrose/citric acid/polymer based binder compositions; and



FIGS. 6 and 7 show the bond strength before and after weathering for dextrose/diammonium phosphate/polymer based binder compositions:



FIG. 6a—dextrose/diammonium phosphate/carboxymethyl cellulose (Mw˜250 kDa),



FIG. 6b—dextrose/diammonium phosphate/chitosan (Mw60 kDa-220 kDa),



FIG. 7a—dextrose/diammonium phosphate/carboxymethyl cellulose (Mw˜250 kDa),



FIG. 7b—dextrose/diammonium phosphate/partially hydrolysed PVA (Mw30 kDa-70 kDa),



FIG. 7c—dextrose/diammonium phosphate/chitosan (Mw60 kDa-220 kDa).





DETAILED DESCRIPTION

The present invention now provides an aqueous curable binder composition comprising the starting materials required for forming a thermoset resin upon curing and a matrix polymer.


The matrix polymer may be of natural and/or synthetic origin. These polymers may act as an active filling agent in the binder formulation, and may form intra- and inter-molecular chain interactions. Naturally derived polymers may advantageously be selected from polysaccharides, such as chitosan, cellulose and its derivatives, such as cellulose ether and ester derivatives. The cellulose ether derivatives can be prepared by carboxymethylation, carboxyethylation and carboxypropylation. Examples of preferred cellulose ether derivatives are: nanocellulose, carboxymethyl cellulose (CMC), sodium carboxymethyl cellulose (NaCMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), ethyl cellulose (EC), trityl cellulose, and so on. The preferred cellulose ester derivatives include acetates, butyrates, benzoates, phthalates and anthranilic acid esters of cellulose, preferably, cellulose acetate phthalate (CAP), cellulose acetate butyrate (CAB), cellulose acetate trimelitate (CAT), hydroxylpropylmethyl cellulose phthalate (HPMCP), succinoyl cellulose, cellulose fuoroate, cellulose carbanilate, and mixtures thereof. In some binder compositions cationic cellulose derivatives may be used. Some binder compositions may comprise other polysaccharides such as alginates, starch, chitin and chitosan, agarose, hyaluronic acid, and their derivatives or copolymers (e.g., graft-copolymer, block copolymer, random copolymers), or mixtures thereof.


Chitosan is a polysaccharide derived from crustacean shells, like shrimp shells. Chitosan may have different molecular weights and deacetylation degrees. Preferred are molecular weights between 500 Daltons and 2·106 Daltons, more preferably between 60×103 and 2×105Da.


Synthetically derived polymers may include polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyurethanes, polyesters, polyvinyls and/or their copolymers, aliphatic isocyanate oligomers, azetidinium groups containing polymer (azetidinium polymer) or mixtures thereof.


In one embodiment the binder formulation may comprise polyacrylate, polymethacrylate or polyacrylamide or mixtures thereof, which may be formed from polymerisation of one or more, typically two or three, monomers, which may be present in differing amounts. Preferably the one of the monomers is a substituted alkyl methacrylate or acrylate monomer. The alkyl group of the substituted alkyl function may have from 1 to 10, preferably 1 to 4 carbon atoms and the substituent group may be an alkoxy group with 1 to 4 carbon atoms, such as a methoxy group, or a dialkylamino group, such as dimethylamino. Particularly preferred acrylate monomers are: 2-methoxyacrylate (MEA), 3,5,5-trimethylhexyl acrylate (TMHA), ethylene glycol acrylate (EGA), 2-ethoxyethyl acrylate (EOEA), ethylene glycol diacrylate (EGDA), ethyl 2-ethylacrylate (EEA), (ethyl-cyano)acrylate (ECA), ethyl 2-propyl acrylate (EPA), ethyl 2-(trimethylsilylmethyl)acrylate (ETMSMA), butyl acrylate (BA), butylcyclohexyl acrylate (BCHA), benzyl 2-propyl acrylate (BPA), carboxyethyl acrylate (CEA), 2-(diethylamino)ethyl acrylate (DEAEA), 2-(diethylamino)propyl acrylate (DEAPA). The examples of preferred metharcylate monomers are: methylmethacrylate (MMA), 2-hydroxyethyl methacrylate (HEMA), 2-methoxymethacrylate (MEMA), 2-(diethylamino) ethyl methacrylate (DEAEMA), 2-aminoethyl methacrylate (AEMA), benzyl methacrylate (BMA), 2-butoxyethyl methacrylate (BEMA), 2-(tert-butylamino)ethyl methacrylate (TBAEMA), cyclohexyl methacrylate (CHMA), ethylene glycol methacrylate (EGMA), 2-(diisopropylamino)ethyl methacrylate (DIPAEMA). Preferred acrylamide/methacrylamide monomers are: alkylacrylamide (AAAm), butylacrylamide (BAAm), diethylacrylamide(DEAAm), N,N-dimethyl acrylamide (DMAAm), ethylacrylamide (EAAm), hydroxyethyl acrylamide (HEAAm), hydroxymethyl acrylamide (HMAAm), N-isopropyl acrylamide (NIPAAm), N,N-diethylmethacrylamide (DEMAAm), N-diphenyl methacrylamide (DPMAAm). Preferred polymers comprise two or more monomers and typically a mixture of MEMA or MEA, and DEAEMA or vise versa, in the range between 5:95 and 95:5 percent by weight, advantageously from 10:90 to 90:10, preferably from 20:80 to 80:20, more preferably from 30:70 to 70:30. Optionally further monomers may be present, such as acrylic acid (AA) or methacrylic acid (MAA) in a weight ratio of 1 to 10 percent, preferably about 5 percent by weight. A suitable polymer includes MEMA, DEAEMA and AA in a ratio of 55:40:5 to 75:20:5. Such polymers may comprise one or more monomers which include an aryl group, such as styrene (St) and optionally a dialkylacrylamide group (alkyl representing 1 to 4 carbon atoms), such as dimethylacrylamide (DMAA); and diethylacrylamide (DEAA). Preferably the polymers comprise two monomers selected from styrene and a dialkylacrylamide. Preferred polymers comprise, or consist of the following monomers: St:DMAA and St:DEAA and which may be present in the range of ratios between 40:60 and 95:5. Additional polymers which may be used in binder formulations of the invention may comprise MEA (2-methoxyacrylate) and a dialkylacrylamide group (alkyl representing 1 to 4 carbon atoms), such as dimethylacrylamide (DMAA); and diethylacrylamide (DEAA). Preferred polymers comprise or consist of MEA:DMAA and MEA:DEAA, which may be present in the ratios between 30-80:70-20 respectively.


According to another embodiment of the invention, the binder composition may comprise a polyurethane matrix polymer which provides bond strength and faster curing. Polyurethane polymers may be formed by polymerising a polydiol with a diisocyanate and optionally with an extender molecule, such as a diol. The extender molecules have the effect of modifying the physical character of the polymers, for example, polymer shape, viscosity and polymer state. The polydiol may be selected from the group consisting of but not limited to, poly(polypropylene glycol)-poly(ethylene glycol) (PPG-PEG), polyethylene glycol (PEG), poly(caprolactone)-diol (PCL-diol), poly(lactic acid)-diol (PLA-diol), poly(glycolic acid)-diol (PGA-diol), poly(tetramethylene glycol) (PTMG) also known as poly(butylene glycol), poly[1,6-hexanediol/neopentyl glycol-alt-(adipic acid)]diol (PHNAD), poly[1,6-hexanediol/neopentyl glycol/diethylene glycol-alt-(adipic acid)]diol (PHNDGAD), poly(dimethyl siloxane)-diol (PDMS). The molecular weight of the polydiol may range from Mn=200 to Mn=7000 and it may be present in an amount of 15-55% by weight, such as 20-50% by weight of the polymer. The diisocyanate may be selected from the group consisting of but not limited to methylene diphenyl diisocyanate (MDI), 1,4-phenylene diisocyanate (PDI), 1,1′-methylenebis(4-isocyanatocyclohexane) (HMDI), 2,4-toluene diisocyanate (TDI), hexamethylene diisocyanate (HDI), 1,3-bis(isocynanatomethyl) cyclohexane (BICH). Typically the diisocyanate is present in an amount of 45-55% by weight of the polymer. Suitable extenders include 1,4-butanediol (BD), ethylene glycol (EG), 2,2,3,3,4,4,5,5-octafluoro-1,6-hexanediol (OFHD); and 3-dimethylamino-1,2-propanediol (DMAPD). When present, the extender may be present in an amount of 10-30 mol % of the polymer, typically 10-25%.


In yet another embodiment, the binder composition may comprise polyesters, copolymers or mixtures (blends) thereof. Non limiting examples of preferred polyesters are: polyglycolide or polyglycolic acid (PGA), polylactic acid (PLA), polycaprolactone (PCL), polyhydroxyalkanoate (PHA), polyhydroxybutyrate (PHB), polyethylene adipate (PEA), polybutylene succinate (PBS), poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polytrimethylene terephthalate (PTT), polyethylene naphthalate (PEN), vectran, and/or their copolymers such as PCL-PLA, PCL-PGA, PLA-PGA, PCL-PLA-PCL, PIBVE-b-PCL, and others.


Furthermore, the binder composition of the invention may comprise vinyl polymers and amic acid based polymers, such as poly(pyromellitic dianhydride-co-4,4′oxodianiline) amic acid. Preferably, these may include polyethylene, polypropylene, polybutadiene, polyvinyl chloride (PVC), polyvinyl acetate (PVAc), polyvinyl alcohol (PVA), partially hydrolized polyvinyl acetate, polyacrylonitrile (PAN), polyvinyl butyral (PVB), and polyvinyl toluene (PVT) and/or their copolymers such as PVA-b-PS, PS-b-PMMA, PS-b-PAN, PVA-PGMA, or mixtures thereof. The above said polymers may be incorporated into the binder formulation in homogeneous (aqueous solution) or heterogeneous (emulsion) systems. The solution or emulsion polymers may be present in the composition in an amount ranging from 0.5% up to 50% by weight based on total solids.


In another preferred embodiment, the binder composition may comprise an azetidinium polymer. Such material is known per se and may be obtained by the reaction of a polyamidoamine and a halohydrin. An azetidinium polymer is made up of at least two monomeric units containing a substituted or unsubstituted four membered nitrogen containing heterocycle. The azetidinium polymer may be a homopolymer or a copolymer comprising one or more non-azetidinium monomer units incorporated into the polymer structure. A preferred polyazetidinium suitable for use in accordance with the invention shows the formula




embedded image



wherein R1 may be C1-C25 alkanediyl, preferably C1-C10 alkanediyl or C1-C5 alkanediyl, possibly substituted with a hydroxyl group, carboxyl functional group or an amine,

  • R2 may be independently R1 or —R3—NH—C(O)—R4—, with R3 and R4 being independently C1-C25 alkanediyl, preferably C1-C10 alkanediyl or C1-C5 alkanediyl,
  • Y1 and Y3 being H or a C1-C5 alkyl group, possibly substituted with a hydroxyl group, an amine or a carboxyl group,
  • Y2 being OH or independently Y1,
  • X being a halogen counter ion.
  • An example of such an azetidinium polymer is the product coded CA1025.


Carbohydrate based binders or binder compositions may comprise polymer micro- and/or nano-particles. Preferred micro- and/or nano-particles derived from natural polymers are selected from polysaccharides, such as chitin and chitosan, cellulose and its derivatives, such as cellulose ether and ester derivatives, alginates, starch, agarose, hyaluronic acid, and their derivatives or copolymers, and mixtures thereof. Preferable nano materials are nanocelluloses such as cellulose nanocrystals or cellulose nanowhiskers or nanofibres and/or mixtures thereof.


Synthetically derived polymer micro- and/or nano-particles particularly suitable for carbohydrate based binders are advantageously selected from polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyurethanes, polyesters, and aliphatic isocyanate oligomers, or copolymers and/or mixtures thereof.


The weight ratio of the matrix polymer may make up from about 1 to 20% dry weight of the binder composition, preferably from about 2 to 18% dry weight, more preferably from 5 to 15% dry weight of the composition.


The said matrix polymers, more specifically the polymers exemplified above, may show a molecular weight ranging from 500 Daltons (Da) to 2×106 Da, preferably from 1×103-5×105 Da, more preferably 5×104 Da-3×105 Da.


One or more pre-formed polymers, or monomers, possibly together with initiator, may be emulsion dispersed or solubilised in the binder composition.


It has been found that by adding additional matrix polymer into the binder composition comprising the starting materials for forming the desired binder resin upon curing, higher bonding strength may be obtained. The addition of such matrix polymer may further reduce the binder loss upon curing of the binder resin. Also, the addition of a matrix polymer reduces the water absorption of the binder, as compared to the same binder which includes no additional matrix polymer.


When a polyester resin type binder is desired, the starting materials are selected from compounds bearing hydroxide functional groups and compounds bearing carboxylic acid functional groups, or anhydride or salt derivatives thereof, such that upon curing under appropriate curing conditions the desired polyester resin is obtained. Such polyester based resins are well known in the technical field. As mentioned above, the hydroxide functional compound may be selected from carbohydrates, such as dextrose, and the compound bearing carboxylic acid functional groups, or anhydride or salt derivatives thereof, may be selected from polycarboxylic acid, anhydride or salt thereof.


The polycarboxylic acid may advantageously be selected from monomeric and polymeric polycarboxylic acids. Illustratively, a monomeric polycarboxylic acid may be a dicarboxylic acid, including, but not limited to, unsaturated aliphatic dicarboxylic acids, saturated aliphatic dicarboxylic acids, aromatic dicarboxylic acids, unsaturated cyclic dicarboxylic acids, saturated cyclic dicarboxylic acids, hydroxy-substituted derivatives thereof, and the like. Or, illustratively, the polycarboxylic acid(s) itself may be a tricarboxylic acid, including, but not limited to, unsaturated aliphatic tricarboxylic acids, saturated aliphatic tricarboxylic acids, aromatic tricarboxylic acids, unsaturated cyclic tricarboxylic acids, saturated cyclic tricarboxylic acids, hydroxy-substituted derivatives thereof, and the like. It is appreciated that any such polycarboxylic acids may be optionally substituted, such as with hydroxy, halo, alkyl, alkoxy, and the like. In one variation, the polycarboxylic acid is the saturated aliphatic tricarboxylic acid, citric acid. Other suitable polycarboxylic acids are contemplated to include, but are not limited to, aconitic acid, adipic acid, azelaic acid, butane tetracarboxylic acid dihydride, butane tricarboxylic acid, chlorendic acid, citraconic acid, dicyclopentadiene-maleic acid adducts, diethylenetriamine pentaacetic acid, adducts of dipentene and maleic acid, ethylenediamine tetraacetic acid (EDTA), fully maleated rosin, maleated tall-oil fatty acids, fumaric acid, glutaric acid, isophthalic acid, itaconic acid, maleated rosin oxidized with potassium peroxide to alcohol then carboxylic acid, maleic acid, malic acid, mesaconic acid, bisphenol A or bisphenol F reacted via the KOLBE-Schmidt reaction with carbon dioxide to introduce 3-4 carboxyl groups, oxalic acid, phthalic acid, sebacic acid, succinic acid, tartaric acid, terephthalic acid, tetrabromophthalic acid, tetrachlorophthalic acid, tetrahydrophthalic acid, trimellitic acid, trimesic acid, and the like, and anhydrides, and combinations thereof. Illustratively, a polymeric polycarboxylic acid may be an acid, for example, polyacrylic acid, polymethacrylic acid, polymaleic acid, and like polymeric polycarboxylic acids, copolymers thereof, anhydrides thereof, and mixtures thereof. Examples of commercially available polyacrylic acids include AQUASET-529 (Rohm & Haas, Philadelphia, Pa., USA), CRITERION 2000 (Kemira, Helsinki, Finland, Europe), NF1 (H. B. Fuller, St. Paul, Minn., USA), and SOKALAN (BASF, Ludwigshafen, Germany, Europe). With respect to SOKALAN, this is a water-soluble polyacrylic copolymer of acrylic acid and maleic acid, having a molecular weight of approximately 4000. AQUASET-529 is a composition containing polyacrylic acid cross-linked with glycerol, also containing sodium hypophosphite as a catalyst. CRITERION 2000 is an acidic solution of a partial salt of polyacrylic acid, having a molecular weight of approximately 2000. With respect to NF1, this is a copolymer containing carboxylic acid functionality and hydroxy functionality, as well as units with neither functionality; NF1 also contains chain transfer agents, such as sodium hypophosphite or organophosphate catalysts.


As described in U.S. Pat. Nos. 5,318,990 and 6,331,350, the polymeric polycarboxylic acid comprises an organic polymer or oligomer containing more than one pendant carboxy group. The polymeric polycarboxylic acid may be a homopolymer or copolymer prepared from unsaturated carboxylic acids including, but not necessarily limited to, acrylic acid, methacrylic acid, crotonic acid, isocrotonic acid, maleic acid, cinnamic acid, 2-methylmaleic acid, itaconic acid, 2-methylitaconic acid, α,β-methyleneglutaric acid, and the like. Alternatively, the polymeric polycarboxylic acid may be prepared from unsaturated anhydrides including, but not necessarily limited to, maleic anhydride, itaconic anhydride, acrylic anhydride, methacrylic anhydride, and the like, as well as mixtures thereof. Methods for polymerizing these acids and anhydrides are well-known in the chemical art. The polymeric polycarboxylic acid may additionally comprise a copolymer of one or more of the aforementioned unsaturated carboxylic acids or anhydrides and one or more vinyl compounds including, but not necessarily limited to, styrene, α-methylstyrene, acrylonitrile, methacrylonitrile, methyl acrylate, ethyl acrylate, n-butyl acrylate, isobutyl acrylate, methyl methacrylate, n-butyl methacrylate, isobutyl methacrylate, glycidyl methacrylate, vinyl methyl ether, vinyl acetate, and the like. Methods for preparing these copolymers are well-known in the art. The polymeric polycarboxylic acids may comprise homopolymers and copolymers of polyacrylic acid. The molecular weight of the polymeric polycarboxylic acid, and in particular polyacrylic acid polymer, may be is less than 10000 Da, less than 5000 Da, or about 3000 Da or less. For example, the molecular weight may be 2000 Da.


The carbohydrate may include one or more reactants having one or more reducing sugars. In one aspect, any carbohydrate reactant should be sufficiently nonvolatile to maximize its ability to remain available for reaction with the amine reactant. The carbohydrate reactant may be a monosaccharide in its aldose or ketose form, including a triose, a tetrose, a pentose, a hexose, or a heptose; or a polysaccharide; or combinations thereof. A carbohydrate reactant may be a reducing sugar, or one that yields one or more reducing sugars in situ under thermal curing conditions. For example, when a triose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, an aldotriose sugar or a ketotriose sugar may be utilized, such as glyceraldehyde and dihydroxyacetone, respectively. When a tetrose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, aldotetrose sugars, such as erythrose and threose; and ketotetrose sugars, such as erythrulose, may be utilized. When a pentose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, aldopentose sugars, such as ribose, arabinose, xylose, and lyxose; and ketopentose sugars, such as ribulose, arabulose, xylulose, and lyxulose, may be utilized. When a hexose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, aldohexose sugars, such as glucose (i.e., dextrose), mannose, galactose, allose, altrose, talose, gulose, and idose; and ketohexose sugars, such as fructose, psicose, sorbose and tagatose, may be utilized. When a heptose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, a ketoheptose sugar such as sedoheptulose may be utilized. Other stereoisomers of such carbohydrate reactants not known to occur naturally are also contemplated to be useful in preparing the binder compositions as described herein. When a polysaccharide serves as the carbohydrate, or is used in combination with monosaccharides, sucrose, lactose, maltose, starch, and cellulose may be utilized. The carbohydrate component may advantageously comprise oligomers or polymers that result from the hydrolysis of a polysaccharide, such as starch, cellulose or molasses. Such hydrolysates are capable of generating reducing sugars in situ and/or already comprise reducing sugars and further may contribute to the effect of the matrix polymer. Preferred are hydrolysates that show a DE (dextrose equivalent) of 25 to 90, preferably 35 to 85, or 45 to 85, most preferably 55 to 80.


When Maillard compounds based binders are desired, that means binders based on the reaction between a reducing sugar and a nitrogen containing compound, the carbohydrate compound may advantageously be selected from the carbohydrates mentioned here above. Among these dextrose is the most preferred. The nitrogen containing compound may advantageously be selected from ammonium salt of inorganic acids or organic acids and amine compounds.


The inorganic acid part of ammonium salt may advantageously be selected from phosphoric, sulphuric, nitric and carbonic acid. Ammonium sulphate and ammonium phosphate are preferred. The organic acid may be selected from the polycarboxylic acids mentioned here above.


The amine compound may advantageously be selected from polyamine functional compounds comprising primary and/or secondary amine functional groups. In illustrative embodiments, the polyamine is a primary polyamine. In one embodiment, the polyamine may be a molecule having the formula of H2N-Q-NH2, wherein Q is an alkyl, cycloalkyl, heteroalkyl, or cycloheteroalkyl, each of which may be optionally substituted. In one embodiment, Q is an alkyl selected from a group consisting of C2-C24. In another embodiment, Q is an alkyl selected from a group consisting of C2-C8. In another embodiment, Q is an alkyl selected from a group consisting of C3-C7. In yet another embodiment, Q is a C6 alkyl. In one embodiment, Q is selected from the group consisting of a cyclohexyl, cyclopentyl or cyclobutyl. In another embodiment, Q is a benzyl. In illustrative embodiments, the polyamine is selected from a group consisting of a di-amine, tri-amine, tetra-amine, and penta-amine. In one embodiment, the polyamine is a diamine selected from a group consisting of 1,6-diaminohexane and 1,5-diamino-2-methylpentane. In a preferred embodiment, the di-amine is 1,6-diaminohexane. In one embodiment, the polyamine is a tri-amine selected from a group consisting of diethylenetriamine, 1-piperazine-ethaneamine, and bis(hexamethylene)triamine. In another embodiment, the polyamine is a tetra-amine such as triethylenetetramine. In another embodiment, the polyamine is a penta-amine, such as tetraethylenepentamine. In another embodiment, the polyamine is selected from polyethyleneimine (PEI), polyninyl amine, polyether amine, polylysine. As is known to the skilled person, several different types of polyethylenimines are available, such as linear polyethylenimines, branched polyethylenimines and dendrimer type polyethylenimine; all are suitable in the binder compositions of the invention. Similarly, polyetheramines may show a linear form and branched forms, and all are believed to be suitable for the generation of binder compositions and, hence, binders of the invention.


The dry weight ratio of carbohydrate to ammonium salt of inorganic or polycarboxylic acid ranges from about 2 to about 15, preferably from about 2.5 to about 13. The matrix polymer may make up from about 1 to 20% dry weight of the binder composition, preferably from about 2 to 18% dry weight, more preferably from 5 to 15% dry weight of the composition.


The binder compositions of the invention and binders produced therefrom are essentially formaldehyde-free (that is comprising less than about 1 ppm formaldehyde based on the weight of the composition) and do not liberate substantial formaldehyde. They furthermore are based on natural, hence renewable, resources.


The invention compositions may obviously further comprise coupling agents, dyes, antifungal agents, antibacterial agents, hydrophobes and other additives known in the art for such binder applications, as may be appropriate. Silicon-containing coupling agents are typically present in such binders, generally in the range from about 0.1 to about 1% by weight based on the weight of the solids in the binder composition. These additives are obviously selected such as not to antagonise the adhesive properties of the binder nor the mechanical and other desired properties of the final product comprising such binder composition or binder produced therefrom, and advantageously comply with stringent environmental and health related requirements.


Without being bound by theory, it is believed that curing generates highly crosslinked high molecular weight polymers. These may be analysed by techniques generally known in the art, including determination of molecular weight, and other known techniques.


According to the present invention, the term “binder composition” is not particularly restricted and generally includes any composition which is capable of binding loosely assembled matter, either as such or upon curing.


As used herein, the term “aqueous” is not particularly limited and generally relates to a solution and/or dispersion which is based on water as a solvent. Said term further includes compositions or mixtures which contain water and one or more additional solvents. An “aqueous binder composition” of the invention may be a solution or partial solution of one or more of said binder components or may be a dispersion, such as an emulsion or suspension.


The solid content of the invention aqueous binder composition may range from 5 to 95 w %, advantageously from 8 to 90 w %, preferably from 10 to 85 w %, based on the weight of the total aqueous binder composition. More specifically, when used as a binder for mineral wool insulation, the solid content of the aqueous binder composition may be in the range from 5 to 25 w %, preferably from 8 to 20 w %, more preferably from 10 to 20 w % or even 12 to 18 w %, based on the weight of the total aqueous binder composition. When used as a binder in wood boards, the solid content of the aqueous binder composition may range from 50 to 95 w %, preferably 50 to 90 w %, more preferably 55 to 85 w % or even 60 to 80 w %, based upon the weight of the total aqueous binder composition.


Binder compositions of the invention may further comprise nano-particles derived from inorganic materials such as metal-oxides, preferably MgO, CaO, Al2O3 and CaCO4. Furthermore, nanoclays may be incorporated in the binder formulations. Such nanoclays include, without being limited to, montmorillonite, bentonite, kaolinite, hectorite, and halloysite and other organically-modified nanoclays, and/or mixtures thereof. Such inorganic materials may be present in an amount ranging from 0.1 to 10 w %, preferably 0.1 to 5 w %, of solid content of the total composition.


The components of the invention binder compositions may be transported separately and combined shortly before use in the relevant manufacturing plant. It is also possible to transport the binder composition as such.


The binders of the invention may be used to bond a collection of non or loosely assembled matter. The collection of matter includes any collection of matter which comprises fibers selected from mineral fibers, including but not limited to slag wool fibers, stone wool fibers, glass fibers, aramid fibers, ceramic fibers, metal fibers, carbon fibers, polyimide fibers, polyester fibers, rayon fibers, and cellulosic fibers. Further examples of collection of matter include particulates such as coal, sand, cellulosic fibers, wood shavings, saw dust, wood pulp, ground wood, wood chips, wood strands, wood layers, other natural fibers, such as jute, flax, hemp, straw, wood veneers, facings and other particles, woven or non-woven materials. According to a specific embodiment of the invention, the collection of matter is selected from wood particles and mineral fibers.


In one illustrative embodiment, the binder composition of the invention may be used to make insulation products, comprising mineral fibers. In such an application, the fibers are bonded together such that they become organized in a fiberglass mat which may then be processed into an insulation product. In such an application, the fibers are generally present in an amount ranging from 70 to 99%.


According to another embodiment of the invention, the binder may be used to bond cellulosic particles, such as cellulosic fibers, wood shavings, wood pulp and other materials commonly used to manufacture composite wood boards, including fiber boards, particle boards, oriented strand boards etc. Such wood boards show nominal thicknesses ranging from 6 to 30 mm and a modulus of Elasticity of at least about 1000 N/mm2, bending strength of at least about 5 N/mm2 and/or an internal bond strength of at least 0.10 N/mm2. In such applications, the binder content in the final wood board may range from about 5 to 30% wt with respect to the total weight of the wood board notably from 9 to 20%.


According to the invention, the aqueous binder composition may be applied in a manner known per se onto the fiber or particular material. The binder composition may preferably be applied by spray application. Other techniques include roll application or mixing and/or tumbling the collection of matter with the binder composition. As water evaporates the binder composition forms a gel that bonds the particulate material together when arranged into a desirable assembly as detailed further herein below. When curing, the reactive binder components are caused to react to form essentially water insoluble macromolecular binder intermingled with matrix polymer. Curing thus imparts increased adhesion, durability and water resistance as compared to uncured binder. Curing may be effected at temperatures between ambient (from about 10 to 25° C.) and up to 280° C.


According to another aspect, the invention covers a process for the preparation of a bonded assembly of fibrous materials or particulate materials by application of binder, curing and water evaporation. The obtained product may then be further processed in suitable process steps to make intermediate or final products, including but not limited to insulation products. More specifically, a process for the manufacturing of an assembly of fibers or cellulosic particles may comprise the successive or concomitant application of the relevant components of the binder composition described here above or the application of an aqueous binder composition as previously described onto a collection of fibers or particles; the gathering of the coated fibers or particles in an assembly; and curing whereby the carbohydrate and ammonium salt components are caused to react to form a macromolecular binder, and evaporating water.


Curing may be effected at a temperature ranging from 90-200° C., preferably higher than 140° C., more preferably lower than 190° C., typically between 160 and 180° C. In the manufacture of wood boards, curing is performed while the material is subjected to pressing


The invention will be explained in more details in the examples below with reference to the attached Figures, in which:

    • FIGS. 1-3 show the cure rate of several binder compositions;
    • FIG. 4 shows the bond strength before and after weathering for dextrose/ammonium sulphate/polymer based binder compositions;
    • FIG. 5 shows the bond strength before and after weathering for dextrose/citric acid/polymer based binder compositions; and
    • FIGS. 6 and 7 show the bond strength before and after weathering for dextrose/diammonium phosphate/polymer based binder compositions.


In the following, examples, the following matrix polymers have been used:

    • Carboxymethyl cellulose (Na CMC)—Mw of approx. 250 kDa
    • Hydroxypropyl cellulose (HPC)—Mw of approx. 100 kDa
    • Hydroxyethyl cellulose (HEC)—Mw of approx. 250 kDa
    • Chitosan (CS)—Mw in the range 60 kDa-220 kDa
    • Partially hydrolysed PVA—Mw in the range of 30 kDa-70 kDa.


Preparation of Binder Compositions

The required amount of matrix polymer was dissolved in water. Similarly, the required amount of dextrose monohydrate (DMH) was dissolved in water separately, followed by addition of ammonium sulphate (AmSO4), diammonium phosphate (DAP) or citric acid monohydrate (CAMH) with constant stirring, as the case may be. Then the desired amount of polymer solution was added to the mixture of DMH solution or vice versa. The mixture was vigorously stirred in order to obtain a homogenous solution, followed by addition of other additives into the solution if applicable and vigorous stirring.


Determination of Cure Rate

A 50 μL sample of binder solution was dispensed onto a spot of a Whatman™ glass microfiber filter surface. Samples were kept on the top shelf in an oven, avoiding high moisture content inside the oven during curing. For each binder solution, samples were cured for different time periods ranging from 1 minute up to 20 minutes, at different temperatures. After curing, each glass filter sample was cut and fully immersed in 50 mL cold water in a 150 mL glass beaker, and then sonicated for 15 minutes at room temperature. The extract solution was filtered and the absorbance of the extract was determined with a spectrophotometer at 470 nm. The absorbance was plotted as a function of cure time. The results of various binder compositions are presented in FIGS. 1-3. As shown in FIG. 1, the matrix polymer addition to DMH/AmSO4 binder compositions shows no significant effect on the cure rate. The addition of matrix polymer to CAMH based binder compositions (FIG. 2) and DAP based binder compositions (FIG. 3) accelerated curing as demonstrated in FIGS. 2 and 3.


Determination of Bond Strength Before and After Weathering

Commercial PF (phenol formaldehyde) impregnated (A4 size) glass fiber veils were placed into a muffle furnace oven for 30 minutes at 600° C. in order to burnout the PF binder, and were then allowed to cool for 30 minutes. The obtained veil samples were weighted.


Approx. 400 g binder solution samples were poured into dip trays, and the obtained veil samples carefully fully immersed into the relevant binder solutions. The impregnated veils were cured at desired temperature for desired periods of time. Binder content was then measured and bond strength determined as follows.


The bond strength of the relevant cured binder impregnated veils was determined by means of a testometric machine (M350-10CT). For each test a cured binder impregnated A4 veil was cut into 8 equal strips. Each strip was tested separately using a 50 Kg load cell (DBBMTCL-50 kg) at an automated test speed of 10 mm/min controlled by winTest Analysis software. Glass veil tensile plates were attached to the testometric machine in order to ensure a 100 mm gap between plates. Samples were placed vertically in the grippers; and the force was tarred to zero. Various parameters such as maximum load at peak, stress at peak and modulus (stiffness) were evaluated by the software, and data presented as an average of 8 samples with standard deviation. The average maximum load at peak or stress at peak defined as the bond strength.


Cured binder impregnated veils were placed in an autoclave (J8341, Vessel: PV02626 with associated safety valve, door interlock and integrated pipework) system. Samples were treated at 90% humidity and at a temperature ranging from 40° C. to 110° C. (full cycle), at a pressure of up to 2.62 bar, for 3 hours. The samples were dried completely in order to ensure no moisture remains onto the veils. The autoclave treated samples were tested for bond strength by means of testometric machine (M350-10CT) described here above, and the results were compared with those of untreated samples.


The evaluation of bond strength was investigated for the veils impregnated with various binder compositions—see FIGS. 4-7. These impregnated veils were cured at 190° C. for 20 minutes and mechanical tests were performed at dry conditions.


In FIG. 4, the results for the following binder compositions are shown: DMH/AmSO4/CS, DMH/AmSO4/NaCMC and DMH/AmSO4/PVA. The bond strength was found to be ˜66N for DMH/AmSO4 (85/15), when CS was added into the binder composition, the bond strength increased significantly. More specifically, the bond strength increased to 96N for DMH/AmSO4/CS (74/13/13) which is 45% higher bond strength as compared to that of DMH/AmSO4(85/15) binder (FIG. 4a). Similarly the bond strength of DMH/AmSO4/NaCMC (particularly for the ratios of 74/13/13, 85/15/10 and 85/15/5) was higher than for DMH/AmSO4 (85/15) (FIG. 4c). In the figures, the values presented in each graph are average values for the corresponding formulations. The dotted lines represent bond strength of binder composition containing no additional matrix polymer.


Bond Strength After Weathering Was Not Significantly Increased by Addition of Matrix Polymer


FIG. 5 shows the bond strength results of various DMH/CAMH/NaCMC binder compositions impregnated into glass fiber veils. When NaCMC (5%) was added into the citric acid based composition, the bond strength increased by ˜23% (FIG. 5). Increase of the NaCMC concentration in the binder composition (DMH/CAMH/NaCMC) does not significantly affect the bond strength.



FIG. 6 shows the bond strength before and after extreme weather treatment. The study was performed with 7% DAP, and the ratio of DMH/polymer was varied. Results (FIG. 6) indicate the bond strength of DMH/DAP (93/7) is increased by addition of CMC or CS matrix polymer. When adding more matrix polymer into the binder composition (93/7), the bond strength remains essentially steady within the range.


The weather stability bond strength of all these DMH/DAP/NaCMC and DMH/DAP/CS compositions was also investigated, and the results are plotted in FIG. 6 too. Results indicate that CS significantly increases the weather stability (compare DMH/DAP/CS to DMH/DAP (93/7)).



FIG. 7 shows the bond strength of DMH/DAP/Polymer compositions before and after full cycle autoclaving: (a) DMH/DAP/NaCMC, (b) DMH/DAP/PVA and (c) DMH/DAP/CS. The values presented in each graph are the average values of the corresponding compositions. The DAP concentration was kept constant (12-13%). Results indicate that both NaCMC and CS significantly increase the bond strength as well as improved the weather stability as compared to that of DMH/DAP (87/13).


Binder Weight Loss Upon Curing

Binder solutions were prepared as described above and weighted samples showing a solids content of 2-5% were poured into aluminium petri dishes and kept in an oven for 2 hours at 140° C. The theoretical and experimental values were determined and the weight loss was calculated. The results obtained for various compositions are shown in Table 1 below. As can be seen, the binder weight loss is significantly reduced with addition of matrix polymer in the compositions.









TABLE 1







Binder weight loss upon curing at 140° C. for 2 hours.









Binder Weight


Formulations (wt. %)
Loss (%)











85% DMH + 15% AmSO4
31.52


80% DMH + 15% AmSO4 + 5% NaCMC
22.76


75% DMH + 15% AmSO4 + 10% NaCMC
16.67


70% DMH + 15% AmSO4 + 15% NaCMC
8.46


80% DMH + 15% AmSO4 + 5% CS
26.76


80% DMH + 15% AmSO4 + 5% PVA
21.65


85% DMH + 15% CAMH
32.75


80.75% DMH + 14.25% CAMH + 5% NaCMC
23.98


80.75% DMH + 14.25% CAMH + 5% PVA
24.72


78.2% DMH + 13.8% CAMH + 8% NaCMC
23.59


78.2% DMH + 13.8% CAMH + 8% PVA
24.68


85% DMH + 15% CAMH
32.75


87% DMH + 13% DAP
32.44


80% DMH + 12% DAP + 8% NaCMC
27.27


80% DMH + 12% DAP + 8% PVA
29.37


82.65% DMH + 12.35% DAP + 5% CS
27.97









Water Absorption

100 g of binder solutions were prepared with desired solid content. Glass microfiber filter GFA were completely immerged and kept for 10 seconds in the relevant binder solutions, and then removed. The binder impregnated GFA samples were cured at desired temperatures, e.g. at 180-190° C. for 10 minutes, and the weight was measured (4 decimal point). Thereafter, the cured GFA samples were fully immerged into a beaker filled with 200 mL water. The samples were maintained for 1 hour under water by means of a glass rod. After 1 hour, the GFA samples were withdrawn and the surface water was absorbed by absorbent paper. The weight of the wet GFA sample was measured. The percentage of water absorption was determined for each sample in three replicates according to the following relationship.

% Water absorption=[(Mass of GFA wet−Mass of GFA dry)/Mass of GFA dry]×100


Table 2 represents water absorption (%) for various compositions of DMH/AmSO4/Polymer, DMH/CAMH/Polymer and DMH/DAP/Polymer, with and without additive (silicone). It can be seen that water absorption is about 247% for standard known DMH/AmSO4 (85/15) binder. With the addition of matrix polymer such as NaCMC and CS the water absorption is significantly reduced, depending on the type and ratio of the matrix polymer used in the formulation. The addition of silicone (1% or 1.5%) in the composition further reduces water absorption significantly.









TABLE 2







Water absorption (%) of DMH/AmSO4/Polymer, DAP/CAMH/Polymer


and DMH/DAP/Polymer binders.










Water




Absorption
STDEV


DMH/AmSO4/Polymer Formulation
(%)
(+/−)












DMH/AmSO4: 85/15
246.64
6.37


DMH/AmSO4/NaCMC: 85/15/5
210.32
0.47


DMH/AmSO4/NaCMC/Silicone: 85/15/5/1
144.85
10.49


DM H/AmSO4/NaCIVIC/Silicone: 85/15/5/1.5
115.36
5.71


DMH/AmSO4/NaCMC/Silicone: 85/15/5/3.0
109.47
1.36


DMH/AmSO4/NaCMC: 85/15/10
153.05
7.36


DMH/AmSO4/NaCMC/Silicone: 85/15/10/1
134.75
3.52


DMH/AmSO4/NaCMC/Silicone: 85/15/10/1.5
112.97
8.42


DMH/AmSO4/NaCMC/Silicone: 85/15/10/3.0
119.52
10.96


DMH/AmSO4/NaCMC 74/13/13
112.67
7.77


DMH/AmSO4/NaCMC/Silicone: 74/13/13/1
130.45
6.55


DMH/AmSO4/NaCMC/Silicone: 74/13/13/1.5
116.80
9.78


DMH/AmSO4/NaCMC/Silicone: 74/13/13/3.0
143.62
1.66


DMH/AmSO4/CS: 85/15/5
198.62
8.98


DMH/AmSO4/CS/Silicone: 85/15/5/1
76.92
0.97


DMH/AmSO4/CS: 85/15/10
145.25
5.78


DMH/AmSO4/CS/Silicone: 85/15/10/1
82.65
4.73


DMH/AmSO4/CS/Silicone: 85/15/10/1.5
79.76
0.56


DMH/CAMH/Polymer Formulation


DMH/CAMH: 85/15
273.55
5.39


DMH/CAMH/NaCMC: 80.75/14.25/5
224.65
8.30


DMH/CAMH/NaCMC/Silicone: 80.75/14.25/5/1
76.33
4.43


DMH/CAMH/NaCMC: 78.2/13.8/8
190.18
12.62


DMH/CAMH/NaCMC/Silicone: 78.2/13.8/8/1
83.97
6.38


DMH/CAMH/NaCMC: 74/13/13
143.25
17.68


DMH/CAMH/NaCMC/Silicone: 74/13/13/1
125.34
3.57


DMH/CAMH/HEC: 74/13/13
198.23
7.78


DMH/CAMH/HEC/Silicone: 74/13/13/1
77.25
6.39


DMH/CAMH/HEC/Silicone: 74/13/13/3
76.35
7.56


DMH/DAP/Polymer Formulation


DMH/DAP: 87/13
261.61
4.62


DMH/DAP/NaCMC: 80/12/8
203.96
7.37


DMH/DAP/PVA: 80/12/8
231.99
10.75










Binder solutions comprising 2% solids were prepared according to the method disclosed above and showed the compositions indicated in the tables below. Bond strength of weathered and unweathered veils impregnated with the relevant binder compositions and cured for 8 minutes at 200° C. were measured as disclosed above. The results are summarized in the tables below, averaged over 8 replicates.












TABLE 3









Bond strength of veils,
Bond strength after weather



unweathered
treatment












Average Bond
STDEV
Average Bond
STDEV


Binder Formulations
Strength (N)
(+/−)
Strength (N)
(+/−)














85% DMH + 15% AmSO4 (control)
63.347
10.896
36.847
7.001


84% DMH + 15% AmSO4 + 1% CS
63.930
4.880
36.278
4.683


83% DMH + 15% AmSO4 + 2% CS
71.741
9.679
40.750
11.168


82% DMH + 15% AmSO4 + 3% CS
73.794
7.956
41.389
6.299


81% DMH + 15% AmSO4 + 4% CS
74.638
3.456
42.615
4.071


80% DMH + 15% AmSO4 + 5% CS
78.263
7.636
45.519
7.849



















TABLE 4









Bond strength of veils,
Bond strength after weather



unweathered
treatment












Average Bond
STDEV
Average Bond



Binder Formulations
Strength (N)
(+/−)
Strength (N)
STDEV (+/−)














49.73% DMH + 35.28% Fructose +
65.56
8.86
49.13
12.91


15% AmSO4 (control)


49.14% DMH + 34.16%
77.22
8.04
56.87
10.69


Fructose + 15% AmSO4 + 1% CS


48.56% DMH + 34.44% Fructose +
80.63
5.39
53.80
9.84


15% AmSO4 + 2% CS


47.97% DMH + 34.03% Fructose +
89.95
8.92
55.39
7.74


5% AmSO4 + 3% CS


47.39% DMH + 33.61% Fructose +
90.35
10.59
55.46
5.87


15% AmSO4 + 4% CS


46.8% DMH + 33.2% Fructose +
93.36
10.44
55.45
4.20


15% AmSO4 + 5% CS



















TABLE 5









Bond strength of
Bond strength after weather



veils unweathered
treatment












Average Bond

Average Bond



Binder Formulations
Strength (N)
STDEV (+/−)
Strength (N)
STDEV(+/−)














93% DMH + 7% DAP (control)
61.879
5.623
47.517
7.113


92% DMH + 7% DAP + 1% CS
76.365
11.618
62.671
7.041


91% DMH + 7% DAP + 2% CS
77.228
19.285
71.698
9.090


90% DMH + 7% DAP + 3% CS
80.586
7.494
65.023
6.975


89% DMH + 7% DAP + 4% CS
83.593
3.745
63.070
6.317


88% DMH + 7% DAP + 5% CS
85.106
8.047
68.655
5.123


87% DMH + 13% DAP
63.593
3.692
56.608
7.624


86% DMH + 13% DAP + 1% CS
83.311
4.994
56.714
9.745


85% DMH + 13% DAP + 2% CS
82.974
7.375
68.743
9.176


84% DMH + 13% DAP + 3% CS
91.810
13.908
74.988
6.892










The data clearly shows the beneficial effect of chitosan polymer matrix (CS) addition to the hydrocarbon based binder compositions.


The experiments were repeated with binder compositions comprising 2% solids. The compositions are shown in the tables below and comprise a polyazetidinium (CA1025) as polymer matrix. Bond strength of weathered and unweathered veils impregnated with the relevant binder compositions and cured for 8 minutes at 200° C. were measured as disclosed above. The results are summarized in Table 6 below, averaged over 8 replicates.












TABLE 6









Bond strength of veils
Bond strength after



unweathered
weather treatment












Average Bond
STDEV
Average Bond
STDEV


Binder Formulations
Strength (N)
(+/−)
Strength (N)
(+/−)














85% DMH + 15% AmSO4
66.812
4.145
52.123
4.542


84% DMH + 15% AmSO4 + 1% CA1025
76.345
11.167
63.410
5.393


83% DMH + 15% AmSO4 + 2% CA1025
91.245
6.388
60.231
10.250


82% DMH + 15% AmSO4 + 3% CA1025
86.144
8.922
61.076
13.230


81% DMH + 15% AmSO4 + 4% CA1025
85.144
11.654
59.530
6.549


80% DMH + 15% AmSO4 + 5% CA1025
90.640
15.134
59.614
4.720


85% DMH + 15% CAMH
84.766
6.047
59.569
10.650


84% DMH + 15% CAMH + 1% CA1025
116.151
8.766
103.040
15.460


83% DMH + 15% CAMH + 2% CA1025
113.480
12.390
99.004
19.273


82% DMH + 15% CAMH + 3% CA1025
108.101
9.386
93.758
14.468


81% DMH + 15% CAMH + 4% CA1025
113.229
11.863
96.023
11.444


93% DMH + 7% DAP
73.499
6.763
61.000
10.738


92% DMH + 7% DAP + 1% CA1025
76.266
9.219
65.361
12.090


91% DMH + 7% DAP + 2% CA1025
86.489
5.461
68.984
10.122


90% DMH + 7% DAP + 3% CA1025
87.264
10.278
69.571
9.345


89% DMH + 7% DAP + 4% CA1025
87.280
6.899
66.944
8.225


87% DMH + 13% DAP
67.843
7.629
59.438
6.947


86% DMH + 13% DAP + 1% CA1025
73.781
15.805
82.893
7.693


85% DMH + 13% DAP + 2% CA1025
87.873
6.696
83.829
8.665


84% DMH + 13% DAP + 3% CA1025
88.965
13.690
85.755
14.067


83% DMH + 13% DAP + 4% CA1025
88.611
7.886
85.308
8.783










Again, the effect on bond strength of the addition of CA1025 is clearly evidenced.
  • DMH: dextrose monohydrate
  • AmSO4: ammonium sulphate
  • DAP: Diammonium phosphate
  • CS: High molecular weight chitosan from Sigma Aldrich, CAS n° 9012-76-4 (419419)
  • CaMH: citric acid monohydrate
  • CA1025: trade name of a commercially available azetidinium polymer


    The experiments were repeated with binder compositions as shown in Table 7 below. Bond strength of weathered and unweathered veils impregnated with the relevant binder compositions and cured for 8 minutes at 200° C. were determined as disclosed above. The results averaged over 8 replicates are shown in Table 7 below.












TABLE 7









Bond Strength of Veils
Bond Strength of Veils



Unweathered
after weather treatment












Average Bond
STDEV
Average Bond
STDEV


Binder Formulations
Strength (N)
(+/−)
Strength (N)
(+/−)














85% DMH + 15% HMDA
72.843
7.760
59.972
10.264


80% DMH + 15% HMDA + 5% HPC
67.175
6.859
53.989
5.306


80% DMH + 15% HMDA + 5% NaCMC
93.310
7.224
77.060
6.285


80% DMH + 15% HMDA + 5% CA1025
85.703
9.744
88.180
7.190


75% DMH + 15% HMDA + 10% CA1025
85.419
12.881
93.776
7.381





DMH: dextrose monohydrate


HMDA: hexamethylene diamine


HPC: hydroxypropyl cellulose


CA1025: trade name of a commercially available azetidinium polymer


Clearly, bond strength of weathered and unweathered veils is essentially maintained or even increased despite reduced dextrose available for reaction with HMDA cross-linker.







Accorder to further aspects, the present invention provides an aqueous curable binder composition, an assembly of fibers or particles and a process as set out in the following aspects:
  • Aspect 1. An aqueous curable binder composition comprising starting materials required for forming a thermoset resin upon curing and a matrix polymer.
  • Aspect 2. The aqueous curable binder composition of aspect 1 comprising a polyhydroxy component, a polycarboxylic acid component, or an anhydride, ester or salt derivative thereof for forming a thermoset resin upon curing, and a matrix polymer.
  • Aspect 3. The aqueous curable binder composition of aspect 2 wherein the polycarboxylic acid component is selected from monomeric and polymeric polycarboxylic acids.
  • Aspect 4. The aqueous curable binder composition of aspect 4 wherein the polycarboxylic acid component is a monomeric polycarboxylic acid, such as dicarboxylic acid, including, but not limited to, unsaturated aliphatic dicarboxylic acids, saturated aliphatic dicarboxylic acids, aromatic dicarboxylic acids, unsaturated cyclic dicarboxylic acids, saturated cyclic dicarboxylic acids, hydroxy-substituted derivatives thereof, or, tricarboxylic acid, including, but not limited to, unsaturated aliphatic tricarboxylic acids, saturated aliphatic tricarboxylic acids, aromatic tricarboxylic acids, unsaturated cyclic tricarboxylic acids, saturated cyclic tricarboxylic acids, hydroxy-substituted derivatives thereof, preferably citric acid, and mixtures thereof.
  • Aspect 5. The aqueous curable binder composition of aspect 2 wherein the salt derivative of the polycarboxylic acid component is an ammonium salt.
  • Aspect 6. The aqueous curable binder composition of any of the preceding aspects wherein the polyhydroxy component is a carbohydrate component selected from monosaccharide in its aldose or ketose form, including a triose, a tetrose, a pentose, a hexose, or a heptose; or a polysaccharide or an oligosaccharide; or a component that yields one or more reducing sugars in situ, or combinations thereof.
  • Aspect 7. The aqueous curable binder composition of aspect 1 comprising a carbohydrate component and a nitrogen containing component for forming a thermoset resin upon curing, and a matrix polymer.
  • Aspect 8. The aqueous curable binder composition of aspect 7 wherein the carbohydrate component is selected from monosaccharide in its aldose or ketose form, including a triose, a tetrose, a pentose, a hexose, or a heptose; or an oligosaccharide or a polysaccharide; or a component that yields one or more reducing sugars in situ, or combinations thereof.
  • Aspect 9. The aqueous curable binder composition of any of aspects 7 or 8 wherein the nitrogen containing component is an ammonium salt of an inorganic acid, selected from phosphoric, sulphuric, nitric and carbonic acid, preferably ammonium sulphate or ammonium phosphate.
  • Aspect 10. The aqueous curable binder composition of any of aspects 7 or 8 wherein the nitrogen containing component is selected from polyamine functional compounds comprising primary and/or secondary and/or tertialy and/or quaternary amine functional groups.
  • Aspect 11. The aqueous curable binder composition of any of aspect 10 wherein the polyamine functional compound has the formula of H2N-Q-NH2, wherein Q is an alkyl, cycloalkyl, heteroalkyl, or cycloheteroalkyl, each of which optionally substituted.
  • Aspect 12. The aqueous curable binder composition of aspect 11 wherein the polyamine functional compound is selected from di-amine, tri-amine, tetra-amine, and penta-amine, more specifically 1,6-diaminohexane and 1,5-diamino-2-methylpentane, diethylenetriamine, 1-piperazineethaneamine, and bis(hexamethylene)triamine, triethylenetetramine, tetraethylenepentamine, polyethyleneimine (PEI), polyninyl amine, polyether amine, polylysine.
  • Aspect 13. The aqueous curable binder composition of any of the preceding aspects wherein the matrix polymer is selected from naturally derived polymers, such as polysaccharides, such as cellulose, starch, alginate, hyaluronic acid, and their derivatives, carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), 2-hydroxyethyl cellulose (HEC), synthetically derived polymers, such as polyvinyls (PVA, PVAc, PAN), polyacrylics, polyacrylate, polymethacrylate, polyacrylamide, polymethacrylamides, polyurethanes, polyesters, aliphatic isocyanate oligomers, polyazetidinium, copolymers thereof and mixtures thereof.
  • Aspect 14. The aqueous curable binder composition of aspect 13 wherein the matrix polymer is selected from cellulose derivatives, such as carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), 2-hydroxyethyl cellulose (HEC); polyvinyl acetate (PVAc), aliphatic isocyanate oligomers, or mixtures thereof.
  • Aspect 15. The aqueous curable binder composition of any of the preceding aspects wherein the matrix polymer shows a molecular weight ranging from 500 Daltons (Da) to 2×106 Da, preferably from 1×103-5×105 Da, more preferably from 5×104 Da-3×105 Da.
  • Aspect 16. The aqueous curable binder composition of any of aspects 7-15 wherein the dry weight ratio of carbohydrate to ammonium salt of inorganic or polycarboxylic acid or polyamine functional compound ranges from about 2 to about 35, preferably from about 2.5 to about 13.
  • Aspect 17. The aqueous curable binder composition of aspect 16 wherein the matrix polymer makes up from about 1 to 20% of the dry weight of the binder composition, preferably from about 2 to 18% dry weight, more preferably from 5 to 15% dry weight of the composition.
  • Aspect 18. The aqueous curable binder composition of any of the preceding aspects further comprising dyes, antifungal agents, antibacterial agents, hydrophobes, silicone containing coupling agents and/or other additives known in the art for such binder compositions.
  • Aspect 19. The aqueous binder composition of any of the preceding aspects wherein a component is selected micro-/or nano-particles derived from natural or synthetic polymers of their combination such as nanocelluloses, or from inorganic materials such as MgO, CaO, Al2O3 and CaCO4, or nanoclays such as montmorillonite, bentonite, kaolinite, hectorite, and halloysite and other organically-modified nanoclays, and/or mixtures thereof.
  • Aspect 20. An assembly of fibers or particles bonded with an aqueous curable binder composition according to any of the preceding aspects or with a binder resulting from the curing of any of the curable binder compositions of the preceding aspects.
  • Aspect 21. The assembly of fibers according to aspect 20 being an insulation product, such as a mineral wool mat or other.
  • Aspect 22. The assembly of particles according to aspect 20 being a composite wood board, such as wood fiber board, wood particle board, plywood or similar board.
  • Aspect 23. A process for the manufacturing of an assembly of fibers or particles according to any of aspects 20-22 characterized in that it comprises the successive or concomitant application of the relevant components of the aqueous curable binder composition of any of aspects 1-19, or the application of an aqueous binder composition according to any of aspects 1 to 19 onto a collection of fibers or particles; the gathering of the coated fibers or particles in an assembly; and curing, whereby the components of the aqueous curable binder composition are caused to react to form a macromolecular binder, and evaporating water.
  • Aspect 24. The process according to aspect 23 characterized in that curing is performed at a temperature ranging from 120° C.-200° C., preferably higher than 140° C., more preferably lower than 190° C., typically between 160 and 180° C.
  • Aspect 25. The process according to any of aspects 23-24 characterized in that the aqueous binder composition is applied by spraying onto the collection of fibers or particles.
  • Aspect 26. The process of any of aspects 23 to 25 wherein the assembly is a wood fiber board or wood particle board or similar wood board, subjected to pressing during curing.

Claims
  • 1. An aqueous curable binder composition consisting of water, starting materials required for forming a thermoset resin upon curing and a matrix polymer, optionally one or more dyes, antifungal agents, antibacterial agents, hydrophobes, and silicone-containing coupling agents, and optionally a component selected from microparticles, nano-particles, or combinations thereof derived from one or more of MgO, CaO, Al2O3, CaCO4, nanoclays, montmorillonite, bentonite, kaolinite, hectorite, and halloysite, wherein the starting materials required for forming a thermoset resin upon curing consist of a carbohydrate component selected from the group consisting of reducing sugars and a carbohydrate component capable of producing one or more reducing sugars in situ under thermal curing conditions, and a nitrogen-containing component and/or a reaction product thereof, and wherein the matrix polymer comprises 5-15% of the dry weight of the binder composition, and is selected from the group consisting of carboxymethyl cellulose (CMC), sodium carboxymethyl cellulose (NaCMC), hydroxypropyl cellulose (HPC), 2-hydroxyethyl cellulose (HEC), chitosan, polyurethanes, aliphatic isocyanate oligomers, azetidinium polymer, copolymers thereof and mixtures thereof.
  • 2. The aqueous curable binder composition of claim 1, wherein the nitrogen-containing component is an ammonium salt of an inorganic acid selected from the group consisting of phosphoric acid, sulphuric acid, nitric acid, carbonic acid and combinations thereof.
  • 3. The aqueous curable binder composition of claim 1, wherein the nitrogen-containing component is selected from the group consisting of polyamine functional compounds comprising one or more of a primary, secondary, tertiary and quaternary amine functional group.
  • 4. The aqueous curable binder composition of claim 3, wherein the polyamine functional compound has the general formula of H2N-Q-NH2, wherein Q is an alkylene, cycloalkylene, heteroalkylene, or cycloheteroalkylene, each of which is optionally substituted.
  • 5. The aqueous curable binder composition of claim 3, wherein the polyamine functional compound is selected from one or more of a diamine, triamine, tetramine, pentamine, 1,6-diaminohexane, 1,5-diamino-2-methylpentane, diethylenetriamine, 1-piperazine-ethaneamine, bis(hexamethylene)triamine, triethylenetetramine, tetraethylenepentamine, polyethyleneimine (PEI), polyvinyl amine, polyether amine, and polylysine.
  • 6. The aqueous curable binder composition of claim 1, wherein the matrix polymer has a molecular weight ranging from about 500 Daltons (Da) to about 2×106 Da.
  • 7. The aqueous curable binder composition of claim 1, wherein the nitrogen-containing component is an ammonium salt of an inorganic acid or is selected from the group consisting of polyamine functional compounds comprising one or more of a primary, secondary, tertiary and quaternary amine functional group, and wherein the dry weight ratio of carbohydrate to ammonium salt of inorganic acid or polyamine functional compound ranges from about 2 to about 35.
  • 8. The aqueous curable binder composition of claim 1, wherein the curable binder composition consists of water, the starting materials required for forming a thermoset resin upon curing, the matrix polymer, and one or more dyes, antifungal agents, antibacterial agents, hydrophobes, and silicone-containing coupling agents.
  • 9. The aqueous curable binder composition of claim 1, wherein the curable binder composition consists of water, the starting materials required for forming a thermoset resin upon curing, the matrix polymer, and a component selected from microparticles, nano-particles, or combinations thereof derived from one or more of MgO, CaO, Al2O3, CaCO4, nanoclays, montmorillonite, bentonite, kaolinite, hectorite, and halloysite.
  • 10. An assembly of fibers or particles bonded with an aqueous curable binder composition according to claim 1 or with a binder resulting from curing of the curable binder composition of claim 1.
  • 11. The assembly of fibers according to claim 10 being an insulation product that is a mineral wool mat.
  • 12. The assembly of particles according to claim 10 being a composite wood board selected from a wood fiber board, wood particle board, and plywood.
  • 13. A process for the manufacturing of an assembly of fibers or particles according to claim 10, said process comprising: successive or concomitant application of the components of the aqueous curable binder composition of claim 1, or application of an aqueous binder composition according to claim 1, onto a collection of fibers or particles to afford coated fibers or coated particles; gathering the coated fibers or coated particles into an assembly; and curing the assembly, whereby water is evaporated and the components of the aqueous curable binder composition are caused to react to form a macromolecular binder.
  • 14. The process according to claim 13 characterized in that curing is performed at a temperature ranging from about 90° C. to about 200° C.
  • 15. The process according to claim 13 characterized in that the aqueous binder composition is applied by spraying onto the collection of fibers or particles.
  • 16. The process of claim 13, wherein the assembly is a wood fiber board or wood particle board subjected to pressing during curing.
  • 17. The aqueous curable binder composition of claim 8, wherein the one or more dyes, antifungal agents, antibacterial agents, hydrophobes and silicone-containing coupling agents are present at a concentration from about 0.1 to about 1% by weight based on the weight of solids in the binder composition.
  • 18. The assembly of fibers or particles of claim 10, wherein the assembly comprises one or more of coal, sand, cellulosic fibers, wood shavings, saw dust, wood pulp, ground wood, wood chips, wood strands, wood layers, natural fibers, jute, flax, hemp, straw, wood veneers, facings, woven and non-woven materials.
Priority Claims (1)
Number Date Country Kind
1412709 Jul 2014 GB national
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 17/386,445, filed Jul. 27, 2021, which is a continuation of U.S. application Ser. No. 17/323,991, filed May 18, 2021, which is a continuation of U.S. application Ser. No. 17/194,269, filed Mar. 7, 2021, which is a continuation of U.S. application Ser. No. 17/129,787 (now abandoned), filed Dec. 21, 2020, which is a continuation of U.S. application Ser. No. 17/063,630 (now abandoned), filed Oct. 5, 2020, which is a continuation of U.S. application Ser. No. 16/941,474 (now abandoned), filed Jul. 28, 2020, which is a continuation of U.S. application Ser. No. 15/931,565 (now abandoned), filed May 13, 2020, which is a continuation of U.S. application Ser. No. 15/326,532, filed Jan. 16, 2017, which is a U.S. national counterpart application of International Application Serial No. PCT/EP2015/066455, filed Jul. 17, 2015, under 35 U.S.C. § 371, which claims priority to GB Application Serial No. 1412709.6, filed Jul. 17, 2014, the disclosures of which are hereby incorporated herein by reference.

US Referenced Citations (486)
Number Name Date Kind
1801052 Meigs Apr 1931 A
1801053 Meigs Apr 1931 A
1886353 Novotny et al. Nov 1932 A
1902948 Castle Mar 1933 A
1964263 Krenke Jun 1934 A
2198874 Leighton Apr 1940 A
2215825 Wallace et al. Sep 1940 A
2261295 Schlack Nov 1941 A
2362086 Eastes et al. Nov 1944 A
2371990 Hanford Mar 1945 A
2392105 Sussman Jan 1946 A
2442989 Sussman Jun 1948 A
2500665 Courtright Mar 1950 A
2518956 Sussman Aug 1950 A
2875073 Gogek Feb 1959 A
2894920 Ramos Jul 1959 A
2965504 Gogek Dec 1960 A
3038462 Bohdan Jun 1962 A
3138473 Floyd et al. Jun 1964 A
3222243 Gaston et al. Dec 1965 A
3231349 Stalego Jan 1966 A
3232821 Banks et al. Feb 1966 A
3297419 Eyre, Jr. Jan 1967 A
3513001 Woodhead et al. May 1970 A
3551365 Matalon Dec 1970 A
3554788 Fechillas Jan 1971 A
3784408 Jaffe et al. Jan 1974 A
3791807 Etzel et al. Feb 1974 A
3802897 Voigt Apr 1974 A
3809664 Burr May 1974 A
3826767 Hoover et al. Jul 1974 A
3856606 Fan et al. Dec 1974 A
3867119 Takeo et al. Feb 1975 A
3907724 Higginbottom Sep 1975 A
3911048 Nistri et al. Oct 1975 A
3919134 Higginbottom Nov 1975 A
3922466 Bell et al. Nov 1975 A
3955031 Jones et al. May 1976 A
3956204 Higginbottom May 1976 A
3961081 McKenzie Jun 1976 A
3971807 Brack Jul 1976 A
4014726 Fargo Mar 1977 A
4028290 Reid Jun 1977 A
4048127 Gibbons et al. Sep 1977 A
4054713 Sakaguchi et al. Oct 1977 A
4085076 Gibbons et al. Apr 1978 A
4097427 Aitken et al. Jun 1978 A
4107379 Stofko Aug 1978 A
4109057 Nakamura et al. Aug 1978 A
4144027 Habib Mar 1979 A
4148765 Nelson Apr 1979 A
4183997 Stofko Jan 1980 A
4184986 Krasnobajew et al. Jan 1980 A
4186053 Krasnobajew et al. Jan 1980 A
4201247 Shannon May 1980 A
4201857 Krasnobajew et al. May 1980 A
4217414 Walon Aug 1980 A
4233432 Curtis, Jr. Nov 1980 A
4246367 Curtis, Jr. Jan 1981 A
4259190 Fahey Mar 1981 A
4265963 Matalon May 1981 A
4278573 Tessler Jul 1981 A
4296173 Fahey Oct 1981 A
4301310 Wagner Nov 1981 A
4310585 Shannon Jan 1982 A
4322523 Wagner Mar 1982 A
4330443 Rankin May 1982 A
4333484 Keritsis Jun 1982 A
4357194 Stofko Nov 1982 A
4361588 Herz Nov 1982 A
4379101 Smith Apr 1983 A
4393019 Geimer Jul 1983 A
4396430 Matalon Aug 1983 A
4400496 Butler et al. Aug 1983 A
4464523 Neigel et al. Aug 1984 A
4506684 Keritsis Mar 1985 A
4520143 Jellinek May 1985 A
4524164 Viswanathan et al. Jun 1985 A
4631226 Jellinek Dec 1986 A
4654259 Stofko Mar 1987 A
4668716 Pepe et al. May 1987 A
4692478 Viswanathan et al. Sep 1987 A
4714727 Hume, III Dec 1987 A
4720295 Bronshtein Jan 1988 A
4734996 Kim et al. Apr 1988 A
4754056 Ansel et al. Jun 1988 A
4761184 Markessini Aug 1988 A
4780339 Lacourse et al. Oct 1988 A
4828643 Newman et al. May 1989 A
4845162 Schmitt et al. Jul 1989 A
4906237 Johansson Mar 1990 A
4912147 Pfoehler et al. Mar 1990 A
4918861 Carpenter et al. Apr 1990 A
4923980 Blomberg May 1990 A
4950444 Deboufie et al. Aug 1990 A
4988780 Das et al. Jan 1991 A
4992519 Mukherjee Feb 1991 A
5001202 Denis et al. Mar 1991 A
5013405 Izard May 1991 A
5032431 Conner et al. Jul 1991 A
5037930 Shih Aug 1991 A
5041595 Yang et al. Aug 1991 A
5089342 Dhein et al. Feb 1992 A
5095054 Lay et al. Mar 1992 A
5106615 Dikstein Apr 1992 A
5114004 Isono et al. May 1992 A
5123949 Thiessen Jun 1992 A
5124369 Vandichel et al. Jun 1992 A
5128407 Layton et al. Jul 1992 A
5143582 Arkens et al. Sep 1992 A
5151465 Le-Khac Sep 1992 A
5167738 Bichot et al. Dec 1992 A
5198492 Stack Mar 1993 A
5217741 Kawachi et al. Jun 1993 A
5218048 Abe et al. Jun 1993 A
5240498 Matalon et al. Aug 1993 A
5244474 Lorcks et al. Sep 1993 A
5278222 Stack Jan 1994 A
5300144 Adams Apr 1994 A
5300192 Hansen et al. Apr 1994 A
5308896 Hansen et al. May 1994 A
5318990 Strauss Jun 1994 A
5336753 Jung et al. Aug 1994 A
5336755 Pape Aug 1994 A
5336766 Koga et al. Aug 1994 A
5340868 Strauss et al. Aug 1994 A
5346541 Goldman Sep 1994 A
5352480 Hansen et al. Oct 1994 A
5367849 Bullock Nov 1994 A
5371194 Ferretti Dec 1994 A
5387665 Misawa et al. Feb 1995 A
5389716 Graves Feb 1995 A
5393849 Srinivasan et al. Feb 1995 A
5416139 Zeiszler May 1995 A
5421838 Gosset et al. Jun 1995 A
5424418 Duflot Jun 1995 A
5434233 Kiely et al. Jul 1995 A
5447977 Hansen et al. Sep 1995 A
5470843 Stahl et al. Nov 1995 A
5480973 Goodlad et al. Jan 1996 A
5492756 Seale et al. Feb 1996 A
5498662 Tanaka et al. Mar 1996 A
5503920 Alkire et al. Apr 1996 A
5534612 Taylor et al. Jul 1996 A
5536766 Seyffer et al. Jul 1996 A
5538783 Hansen et al. Jul 1996 A
5543215 Hansen et al. Aug 1996 A
5545279 Hall et al. Aug 1996 A
5547541 Hansen et al. Aug 1996 A
5547745 Hansen et al. Aug 1996 A
5550189 Qin et al. Aug 1996 A
5554730 Woiszwillo et al. Sep 1996 A
5562740 Cook et al. Oct 1996 A
5571618 Hansen et al. Nov 1996 A
5578678 Hartmann et al. Nov 1996 A
5580856 Prestrelski et al. Dec 1996 A
5582682 Ferretti Dec 1996 A
5583193 Aravindakshan et al. Dec 1996 A
5589256 Hansen et al. Dec 1996 A
5589536 Golino et al. Dec 1996 A
5607759 Hansen et al. Mar 1997 A
5608011 Eck et al. Mar 1997 A
5609727 Hansen et al. Mar 1997 A
5614570 Hansen et al. Mar 1997 A
5620940 Birbara et al. Apr 1997 A
5621026 Tanaka et al. Apr 1997 A
5633298 Arfaei et al. May 1997 A
5641561 Hansen et al. Jun 1997 A
5643978 Darwin et al. Jul 1997 A
5645756 Dubin et al. Jul 1997 A
5660904 Andersen et al. Aug 1997 A
5661213 Arkens et al. Aug 1997 A
5670585 Taylor et al. Sep 1997 A
5672418 Hansen et al. Sep 1997 A
5672659 Shalaby et al. Sep 1997 A
5690715 Schiwek Nov 1997 A
5691060 Levy Nov 1997 A
5693411 Hansen et al. Dec 1997 A
5719092 Arrington Feb 1998 A
5719228 Taylor et al. Feb 1998 A
5733624 Syme et al. Mar 1998 A
5756580 Natori et al. May 1998 A
5763524 Arkens et al. Jun 1998 A
5788243 Harshaw et al. Aug 1998 A
5788423 Perkins Aug 1998 A
5807364 Hansen Sep 1998 A
5855987 Margel et al. Jan 1999 A
5863985 Shalaby et al. Jan 1999 A
5885337 Nohr et al. Mar 1999 A
5895804 Lee et al. Apr 1999 A
5905115 Luitjes et al. May 1999 A
5916503 Rettenbacher Jun 1999 A
5919528 Huijs et al. Jul 1999 A
5919831 Philipp Jul 1999 A
5922403 Tecle Jul 1999 A
5925722 Exner et al. Jul 1999 A
5929184 Holmes-Farley et al. Jul 1999 A
5929196 Kissel et al. Jul 1999 A
5932344 Ikemoto et al. Aug 1999 A
5932665 DePorter et al. Aug 1999 A
5932689 Arkens et al. Aug 1999 A
5942123 McArdle Aug 1999 A
5954869 Elfersy et al. Sep 1999 A
5977224 Cheung et al. Nov 1999 A
5977232 Arkens et al. Nov 1999 A
5981719 Woiszwillo et al. Nov 1999 A
5983586 Berdan, II et al. Nov 1999 A
5990216 Cai et al. Nov 1999 A
5993709 Bonomo et al. Nov 1999 A
6022615 Rettenbacher Feb 2000 A
6067821 Jackson et al. May 2000 A
6071549 Hansen Jun 2000 A
6071994 Hummerich et al. Jun 2000 A
6072086 James et al. Jun 2000 A
6077883 Taylor et al. Jun 2000 A
6090925 Woiszwillo et al. Jul 2000 A
6114033 Ikemoto et al. Sep 2000 A
6114464 Reck et al. Sep 2000 A
6133347 Vickers, Jr. et al. Oct 2000 A
6136916 Arkens et al. Oct 2000 A
6139619 Zaretskiy et al. Oct 2000 A
6143243 Gershun et al. Nov 2000 A
6171444 Nigam Jan 2001 B1
6171654 Salsman et al. Jan 2001 B1
6180037 Anderson et al. Jan 2001 B1
6194512 Chen et al. Feb 2001 B1
6210472 Kwan et al. Apr 2001 B1
6221958 Shalaby et al. Apr 2001 B1
6221973 Arkens et al. Apr 2001 B1
6231721 Quick et al. May 2001 B1
6274661 Chen et al. Aug 2001 B1
6281298 Papsin, Jr. Aug 2001 B1
6299677 Johnson et al. Oct 2001 B1
6299936 Reck et al. Oct 2001 B1
6307732 Tsubaki et al. Oct 2001 B1
6310227 Sarama et al. Oct 2001 B1
6313102 Colaco et al. Nov 2001 B1
6319683 James et al. Nov 2001 B1
6331350 Taylor et al. Dec 2001 B1
6331513 Zaid et al. Dec 2001 B1
6340411 Hansen et al. Jan 2002 B1
6348530 Reck et al. Feb 2002 B1
6365079 Winkler et al. Apr 2002 B1
6372077 Tecle Apr 2002 B1
6379739 Formanek et al. Apr 2002 B1
6379814 Dupre et al. Apr 2002 B1
6395856 Petty et al. May 2002 B1
6403665 Sieker et al. Jun 2002 B1
6407225 Mang et al. Jun 2002 B1
6410036 De Rosa et al. Jun 2002 B1
6440204 Rogols et al. Aug 2002 B1
6441122 DeMott et al. Aug 2002 B1
6461553 Hansen et al. Oct 2002 B1
6468442 Bytnar Oct 2002 B2
6468730 Fujiwara et al. Oct 2002 B2
6469120 Elfersy et al. Oct 2002 B1
6475552 Shah et al. Nov 2002 B1
6482875 Lorenz et al. Nov 2002 B2
6482876 Witt-Nuesslein et al. Nov 2002 B1
6495656 Haile et al. Dec 2002 B1
6521339 Hansen et al. Feb 2003 B1
6525009 Sachdev et al. Feb 2003 B2
6538057 Wildburg et al. Mar 2003 B1
6547867 Rogols et al. Apr 2003 B2
6555616 Helbing et al. Apr 2003 B1
6559302 Shah et al. May 2003 B1
6562267 Hansen et al. May 2003 B1
6596103 Hansen et al. Jul 2003 B1
6613378 Erhan et al. Sep 2003 B1
6638882 Helbing et al. Oct 2003 B1
6638884 Quick et al. Oct 2003 B2
6699945 Chen et al. Mar 2004 B1
6706853 Stanssens et al. Mar 2004 B1
6719862 Quick et al. Apr 2004 B2
6730730 Hansen et al. May 2004 B1
6753361 Kroner et al. Jun 2004 B2
6818694 Hindi et al. Nov 2004 B2
6821547 Shah et al. Nov 2004 B2
6852247 Bytnar Feb 2005 B2
6858074 Anderson et al. Feb 2005 B2
6861495 Barsotti et al. Mar 2005 B2
6864044 Ishikawa et al. Mar 2005 B2
6878800 Husemoen et al. Apr 2005 B2
6884849 Chen et al. Apr 2005 B2
6955844 Tagge et al. Oct 2005 B2
6962714 Hei et al. Nov 2005 B2
6989171 Portman Jan 2006 B2
6992203 Trusovs Jan 2006 B2
7018490 Hansen et al. Mar 2006 B2
7026390 O'Brien-Bernini Apr 2006 B2
7029717 Ojima et al. Apr 2006 B1
7067579 Taylor et al. Jun 2006 B2
7083831 Koch et al. Aug 2006 B1
7090745 Beckman et al. Aug 2006 B2
7141626 Rodrigues et al. Nov 2006 B2
7144474 Hansen et al. Dec 2006 B1
7195792 Boston et al. Mar 2007 B2
7201778 Smith et al. Apr 2007 B2
7201825 Dezutter et al. Apr 2007 B2
7202326 Kuroda et al. Apr 2007 B2
7241487 Taylor et al. Jul 2007 B2
7458235 Beaufils et al. Dec 2008 B2
7514027 Horres et al. Apr 2009 B2
7655711 Swift et al. Feb 2010 B2
7772347 Swift et al. Aug 2010 B2
7795354 Srinivasan et al. Sep 2010 B2
7803879 Srinivasan et al. Sep 2010 B2
7807771 Swift et al. Oct 2010 B2
7842382 Helbing Nov 2010 B2
7854980 Jackson et al. Dec 2010 B2
7883693 Sehl et al. Feb 2011 B2
7888445 Swift et al. Feb 2011 B2
7947765 Swift et al. May 2011 B2
8114210 Hampson et al. Feb 2012 B2
8182648 Swift et al. May 2012 B2
8211923 Wagner et al. Jul 2012 B2
8232334 Kelly Jul 2012 B2
8372900 Shooshtari et al. Feb 2013 B2
8377564 Shooshtari et al. Feb 2013 B2
8501838 Jackson et al. Aug 2013 B2
8680224 Zhang et al. Mar 2014 B2
8691934 Helbing et al. Apr 2014 B2
8900495 Pacorel et al. Dec 2014 B2
9394431 Alavi Jul 2016 B2
10208414 Lester et al. Feb 2019 B2
20010017427 Rosthauser et al. Aug 2001 A1
20010046824 Nigam Nov 2001 A1
20020000100 Burg et al. Jan 2002 A1
20020025435 Hansen et al. Feb 2002 A1
20020026025 Kuo et al. Feb 2002 A1
20020028857 Holy Mar 2002 A1
20020032253 Lorenz et al. Mar 2002 A1
20020042473 Trollsas et al. Apr 2002 A1
20020091185 Taylor et al. Jul 2002 A1
20020096278 Foster et al. Jul 2002 A1
20020123598 Sieker et al. Sep 2002 A1
20020130439 Kroner et al. Sep 2002 A1
20020161108 Schultz et al. Oct 2002 A1
20020197352 Portman Dec 2002 A1
20030005857 Minami et al. Jan 2003 A1
20030040239 Toas et al. Feb 2003 A1
20030044513 Shah et al. Mar 2003 A1
20030066523 Lewis et al. Apr 2003 A1
20030071879 Swenson Apr 2003 A1
20030116294 Kehrer et al. Jun 2003 A1
20030134945 Capps Jul 2003 A1
20030148084 Trocino Aug 2003 A1
20030153690 Husemoen et al. Aug 2003 A1
20030185991 Wigger et al. Oct 2003 A1
20030203117 Bartkowiak et al. Oct 2003 A1
20040002567 Chen et al. Jan 2004 A1
20040019168 Soerens et al. Jan 2004 A1
20040024170 Husemoen et al. Feb 2004 A1
20040033269 Hei et al. Feb 2004 A1
20040033747 Miller et al. Feb 2004 A1
20040034154 Tutin et al. Feb 2004 A1
20040038017 Tutin et al. Feb 2004 A1
20040048531 Belmares et al. Mar 2004 A1
20040077055 Fosdick et al. Apr 2004 A1
20040079499 Dezutter et al. Apr 2004 A1
20040087024 Bellocq et al. May 2004 A1
20040087719 Rautschek et al. May 2004 A1
20040122166 O'Brien-Bernini et al. Jun 2004 A1
20040131874 Tutin et al. Jul 2004 A1
20040144706 Beaufils et al. Jul 2004 A1
20040152824 Dobrowolski Aug 2004 A1
20040161993 Tripp et al. Aug 2004 A1
20040209851 Nelson et al. Oct 2004 A1
20040213930 Halabisky Oct 2004 A1
20040220368 Li et al. Nov 2004 A1
20040249066 Heinzman et al. Dec 2004 A1
20040254285 Rodrigues et al. Dec 2004 A1
20040260082 Van Der Wilden et al. Dec 2004 A1
20050001198 Bytnar Jan 2005 A1
20050017394 Hochsmann et al. Jan 2005 A1
20050027283 Richard et al. Feb 2005 A1
20050033037 Trusovs Feb 2005 A1
20050048212 Clamen et al. Mar 2005 A1
20050059770 Srinivasan et al. Mar 2005 A1
20050171085 Pinto et al. Aug 2005 A1
20050196421 Hunter et al. Sep 2005 A1
20050202224 Helbing Sep 2005 A1
20050208852 Weber Sep 2005 A1
20050215153 Cossement et al. Sep 2005 A1
20050245669 Clungeon et al. Nov 2005 A1
20050275133 Cabell et al. Dec 2005 A1
20050288479 Kuroda et al. Dec 2005 A1
20060005580 Espiard et al. Jan 2006 A1
20060009569 Charbonneau et al. Jan 2006 A1
20060044302 Chen Mar 2006 A1
20060099870 Garcia et al. May 2006 A1
20060111480 Hansen et al. May 2006 A1
20060124538 Morcrette et al. Jun 2006 A1
20060135433 Murray et al. Jun 2006 A1
20060141177 Ligtenberg et al. Jun 2006 A1
20060179892 Horres et al. Aug 2006 A1
20060188465 Perrier et al. Aug 2006 A1
20060198954 Frechem et al. Sep 2006 A1
20060231487 Bartley et al. Oct 2006 A1
20060252855 Pisanova et al. Nov 2006 A1
20060281622 Maricourt et al. Dec 2006 A1
20070006390 Clamen et al. Jan 2007 A1
20070009582 Madsen et al. Jan 2007 A1
20070027281 Michl et al. Feb 2007 A1
20070039520 Crews et al. Feb 2007 A1
20070082983 Crews et al. Apr 2007 A1
20070123679 Swift et al. May 2007 A1
20070123680 Swift et al. May 2007 A1
20070129522 Burckhardt et al. Jun 2007 A1
20070142596 Swift et al. Jun 2007 A1
20070158022 Heep et al. Jul 2007 A1
20070184740 Keller et al. Aug 2007 A1
20070191574 Miller et al. Aug 2007 A1
20070270070 Othman Nov 2007 A1
20070287018 Tutin et al. Dec 2007 A1
20070292618 Srinivasan et al. Dec 2007 A1
20070292619 Srinivasan et al. Dec 2007 A1
20070298274 Eriksson et al. Dec 2007 A1
20080009209 Clamen et al. Jan 2008 A1
20080009616 Frank et al. Jan 2008 A1
20080051539 Kelly Feb 2008 A1
20080060551 Crews et al. Mar 2008 A1
20080081138 Moore et al. Apr 2008 A1
20080108741 Van Herwijnen et al. May 2008 A1
20080160260 Wada et al. Jul 2008 A1
20080160302 Asrar et al. Jul 2008 A1
20080194738 Crews et al. Aug 2008 A1
20090169867 Kelly Jul 2009 A1
20090170978 Kelly Jul 2009 A1
20090227732 Glockner et al. Sep 2009 A1
20090275699 Zhang et al. Nov 2009 A1
20090301972 Hines et al. Dec 2009 A1
20090304919 Huenig et al. Dec 2009 A1
20090306255 Patel et al. Dec 2009 A1
20090324915 Swift et al. Dec 2009 A1
20100029160 Srinivasan et al. Feb 2010 A1
20100058661 Jackson et al. Mar 2010 A1
20100080976 Jackson et al. Apr 2010 A1
20100084598 Jackson et al. Apr 2010 A1
20100086726 Jackson et al. Apr 2010 A1
20100087571 Jackson et al. Apr 2010 A1
20100098947 Inoue et al. Apr 2010 A1
20100117023 Dopico et al. May 2010 A1
20100129593 Rempt et al. May 2010 A1
20100129640 Kelly May 2010 A1
20100130649 Swift et al. May 2010 A1
20100175826 Huenig et al. Jul 2010 A1
20100210595 Wagner et al. Aug 2010 A1
20100222463 Brady et al. Sep 2010 A1
20100222566 Fosdick et al. Sep 2010 A1
20100282996 Jaffrennou et al. Nov 2010 A1
20100301256 Hampson et al. Dec 2010 A1
20100320113 Swift Dec 2010 A1
20110021672 Crews et al. Jan 2011 A1
20110039111 Shooshtari Feb 2011 A1
20110040010 Shooshtari Feb 2011 A1
20110042303 Shooshtari et al. Feb 2011 A1
20110045966 Shooshtari et al. Feb 2011 A1
20110089074 Jackson et al. Apr 2011 A1
20110135937 Swift et al. Jun 2011 A1
20110190425 Swift Aug 2011 A1
20110220835 Swift et al. Sep 2011 A1
20110223364 Hawkins Sep 2011 A1
20110256790 Toas et al. Oct 2011 A1
20110260094 Hampson et al. Oct 2011 A1
20110262648 Lee et al. Oct 2011 A1
20110263757 Rand et al. Oct 2011 A1
20110306726 Bailey et al. Dec 2011 A1
20120133073 Pacorel et al. May 2012 A1
20120135152 Finch May 2012 A1
20120156954 Eckert et al. Jun 2012 A1
20130029150 Appley et al. Jan 2013 A1
20130032749 Jaffrennou et al. Feb 2013 A1
20130047888 Mueller et al. Feb 2013 A1
20130059075 Appley et al. Mar 2013 A1
20130082205 Mueller et al. Apr 2013 A1
20130174758 Mueller Jul 2013 A1
20130234362 Swift et al. Sep 2013 A1
20130236650 Swift et al. Sep 2013 A1
20130237113 Swift et al. Sep 2013 A1
20130244524 Swift et al. Sep 2013 A1
20130323492 Finch et al. Dec 2013 A1
20140083328 Lochel, Jr. Mar 2014 A1
20140091247 Jackson et al. Apr 2014 A1
20140134909 Guo et al. May 2014 A1
20140357787 Jobber et al. Dec 2014 A1
Foreign Referenced Citations (134)
Number Date Country
8538765 Aug 1985 AU
9640921 Jul 1997 AU
1090026 Nov 1980 CA
2037214 Sep 1991 CA
2232334 Nov 1998 CA
2458333 Dec 1999 CA
2278946 Jan 2000 CA
2470783 Dec 2004 CA
1251738 May 2000 CN
1905054 Aug 1969 DE
4142261 Jun 1993 DE
4233622 Apr 1994 DE
4308089 Sep 1994 DE
102004033561 Sep 2005 DE
102005023431 Nov 2006 DE
0044614 Jan 1982 EP
0099801 Feb 1984 EP
354023 Feb 1990 EP
0375235 Jun 1990 EP
0461995 Dec 1991 EP
0524518 Jan 1993 EP
0547819 Jun 1993 EP
0583086 Feb 1994 EP
0714754 Jun 1996 EP
796681 Sep 1997 EP
0826710 Mar 1998 EP
856494 Aug 1998 EP
0873976 Oct 1998 EP
878135 Nov 1998 EP
0882756 Dec 1998 EP
0911361 Apr 1999 EP
915811 May 1999 EP
936060 Aug 1999 EP
976866 Feb 2000 EP
0990729 Apr 2000 EP
1038433 Sep 2000 EP
1193288 Apr 2002 EP
1084167 Sep 2002 EP
1268702 Jan 2003 EP
1382642 Jan 2004 EP
1486547 Dec 2004 EP
1522642 Apr 2005 EP
1698598 Sep 2006 EP
1767566 Apr 2007 EP
2223941 Sep 2010 EP
2253663 Nov 2010 EP
2669349 Dec 2013 EP
2679624 Jan 2014 EP
2692810 Feb 2014 EP
3221412 Sep 2017 EP
2614388 Oct 1988 FR
770561 Mar 1957 GB
809675 Mar 1959 GB
926749 May 1963 GB
1391172 Apr 1975 GB
1469331 Apr 1977 GB
1512066 May 1978 GB
1525541 Sep 1978 GB
2047258 Nov 1980 GB
2078805 Jan 1982 GB
2173523 Oct 1986 GB
2251438 Jul 1992 GB
53113784 Oct 1978 JP
57101100 Jun 1982 JP
58011193 Jan 1983 JP
61195647 Aug 1986 JP
3-173680 Jul 1991 JP
05186635 Jul 1993 JP
7-034023 Feb 1995 JP
09157627 Jun 1997 JP
10234314 Sep 1998 JP
11035491 Feb 1999 JP
11181690 Jul 1999 JP
2000327841 Nov 2000 JP
2002293576 Oct 2002 JP
2003147276 May 2003 JP
2003238921 Aug 2003 JP
2004060058 Feb 2004 JP
2005306919 Nov 2005 JP
549563 Jan 2008 NZ
1765996 Aug 1995 RU
374400 Mar 1973 SU
1990007541 Jul 1990 WO
1992012198 Jul 1992 WO
1995034517 Dec 1995 WO
1997049646 Dec 1997 WO
1999036368 Jul 1999 WO
199947765 Sep 1999 WO
199960042 Nov 1999 WO
199960043 Nov 1999 WO
200058085 Oct 2000 WO
2001014491 Mar 2001 WO
2001059026 Aug 2001 WO
200200429 Jan 2002 WO
200206178 Jan 2002 WO
2003029496 Apr 2003 WO
2003071879 Sep 2003 WO
2003106561 Dec 2003 WO
2004007615 Jan 2004 WO
2004061038 Jul 2004 WO
2004076734 Sep 2004 WO
2005061647 Jul 2005 WO
2005087837 Sep 2005 WO
2006044302 Apr 2006 WO
2006136614 Dec 2006 WO
2007014236 Feb 2007 WO
2007024020 Mar 2007 WO
2007050964 May 2007 WO
2007112335 Oct 2007 WO
2008089851 Jul 2008 WO
WO-2008089847 Jul 2008 WO
2008141201 Nov 2008 WO
2009019235 Feb 2009 WO
2009079254 Jun 2009 WO
2009129084 Oct 2009 WO
2010027937 Mar 2010 WO
2010106181 Sep 2010 WO
2010139899 Dec 2010 WO
2011019590 Feb 2011 WO
2011019593 Feb 2011 WO
2011019597 Feb 2011 WO
2011019598 Feb 2011 WO
2011022224 Feb 2011 WO
2011022226 Feb 2011 WO
2011022227 Feb 2011 WO
2011042610 Apr 2011 WO
2011044490 Apr 2011 WO
2011138459 Nov 2011 WO
2011150203 Dec 2011 WO
2012172265 Dec 2012 WO
2013021112 Feb 2013 WO
2013036752 Mar 2013 WO
2013150123 Oct 2013 WO
2014001518 Jan 2014 WO
Non-Patent Literature Citations (255)
Entry
Nov. 16, Office action for co-pending U.S. Appl. No. 15/326,532 (9 pages)—Nov. 16, 2018.
Office action for co-pending U.S. Appl. No. 15/326,532 (11 pages)—Mar. 14, 2019.
Office action for co-pending U.S. Appl. No. 15/326,532 (9 pages)—Aug. 6, 2019.
Office action for co-pending U.S. Appl. No. 15/326,532 (8 pages)—Dec. 17, 2019.
International Search Report and Written Opinion for PCT/EP2015/066455, completed Oct. 26, 2015.
Office action for co-pending U.S. Appl. No. 12/667,718 (5 pages)—Sep. 3, 2013.
Office action for co-pending U.S. Appl. No. 12/667,718 (6 pages)—Sep. 9, 2014.
Office action for co-pending U.S. Appl. No. 12/671,922 (10 pages)—Oct. 7, 2011.
Office action for co-pending U.S. Appl. No. 12/671,922 (10 pages)—May 10, 2012.
Office action for co-pending U.S. Appl. No. 12/671,922 (9 pages)—Sep. 23, 2014.
Office action for co-pending U.S. Appl. No. 12/671,922 (5 pages)—Apr. 4, 2016.
Office action for co-pending U.S. Appl. No. 13/388,408 (5 pages)—Aug. 15, 2013.
Office action for co-pending U.S. Appl. No. 13/371,829 (9 pages)—Dec. 20, 2012.
Office action for co-pending U.S. Appl. No. 13/371,829 (6 pages)—Jul. 12, 2013.
Office action for co-pending U.S. Appl. No. 13/371,829 (6 pages)—Aug. 12, 2014.
Office action for co-pending U.S. Appl. No. 13/637,794 (8 pages)—Aug. 12, 2013.
Office action for co-pending U.S. Appl. No. 13/637,794 (9 pages)—Mar. 26, 2014.
Office action for co-pending U.S. Appl. No. 13/696,439 (11 pages)—Jan. 8, 2014.
Office action for co-pending U.S. Appl. No. 13/696,452 (7 pages)—Jan. 13, 2015.
Office action for co-pending U.S. Appl. No. 13/696,452 (9 pages)—Oct. 27, 2015.
Office action for co-pending U.S. Appl. No. 13/702,144 (6 pages)—Jan. 10, 2014.
Office action for co-pending U.S. Appl. No. 13/702,144 (7 pages)—Jul. 29, 2014.
Office action for co-pending U.S. Appl. No. 13/823,818 (9 pages)—Mar. 26, 2015.
Office action for co-pending U.S. Appl. No. 13/866,368 (16 pages)—Aug. 29, 2013.
Office action for co-pending U.S. Appl. No. 13/866,368 (11 pages)—Apr. 16, 2014.
Office action for co-pending U.S. Appl. No. 13/866,368 (8 pages)—Aug. 21, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (14 pages)—Sep. 20, 2013.
Office action for co-pending U.S. Appl. No. 13/866,419 (10 pages)—Apr. 25, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (8 pages)—Oct. 9, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (8 pages)—Sep. 25, 2015.
Office action for co-pending U.S. Appl. No. 13/868,233 (23 pages)—Aug. 13, 2013.
Office action for co-pending U.S. Appl. No. 13/868,233 (12 pages)—Apr. 15, 2014.
Office action for co-pending U.S. Appl. No. 13/868,233 (8 pages)—Oct. 7, 2014.
Office action for co-pending U.S. Appl. No. 13/868,233 (8 pages)—Jul. 16, 2015.
Office action for co-pending U.S. Appl. No. 13/868,238 (8 pages)—Jul. 16, 2014.
Office action for co-pending U.S. Appl. No. 12/976,379 (7 pages)—Jan. 10, 2012.
Office action for co-pending U.S. Appl. No. 12/976,379 (6 pages)—Jul. 27, 2012.
Office action for co-pending U.S. Appl. No. 12/976,379 (9 pages)—Mar. 7, 2013.
Office action for co-pending U.S. Appl. No. 12/976,379 (8 pages)—Aug. 20, 2013.
Office action for co-pending U.S. Appl. No. 12/599,858 (8 pages)—May 11, 2011.
Office action for co-pending U.S. Appl. No. 13/341,542 (8 pages)—Dec. 26, 2012.
Office action for co-pending U.S. Appl. No. 13/341,542 (7 pages)—Feb. 10, 2014.
Office action for co-pending U.S. Appl. No. 14/026,394 (6 pages)—Aug. 14, 2014.
Office action for co-pending U.S. Appl. No. 14/272,556 (14 pages)—Nov. 20, 2014.
Office action for co-pending U.S. Appl. No. 14/272,556 (12 pages)—Sep. 17, 2015.
Office action for co-pending U.S. Appl. No. 14/342,069 (17 pages)—Dec. 29, 2015.
Office action for co-pending U.S. Appl. No. 14/342,069 (22 pages)—Sep. 2, 2016.
Office action for co-pending U.S. Appl. No. 14/342,069 (21 pages)—Sep. 26, 2017.
Office action for co-pending U.S. Appl. No. 14/342,069 (21 pages)—Jun. 6, 2018.
Office action for co-pending U.S. Appl. No. 14/390,445 (14 pages)—Dec. 3, 2015.
Office action for co-pending U.S. Appl. No. 14/649,277 (9 pages)—Jul. 22, 2016.
Office action for co-pending U.S. Appl. No. 14/686,915 (8 pages)—Nov. 18, 2016.
Office action for co-pending U.S. Appl. No. 14/810,765 (7 pages)—Jan. 29, 2016.
Office action for co-pending U.S. Appl. No. 14/828,916 (8 pages)—Nov. 25, 2016.
Office action for co-pending U.S. Appl. No. 14/867,502 (9 pages)—Nov. 18, 2016.
International Search Report and Written Opinion for PCT/US2008/059730, completed Sep. 22, 2008.
International Search Report and Written Opinion for PCT/US2008/069046, completed Sep. 25, 2008.
International Search Report and Written Opinion for PCT/EP2011/059317, completed Jul. 15, 2011.
International Search Report for PCT/EP2008/060185, completed Oct. 23, 2008.
International Search Report for PCT/EP2011/057363, completed Sep. 5, 2011.
Ames, J.M., “The Maillard Browning Reaction—an Update,” Chemistry & Industry, No. 17, 1988, 4 pages.
“Gamma-aminopropyltrimethoxysilane,” Hawley's Condensed Chemical Dictionary, 14th Edition, John Wiley & Sons, Inc., 2002, 1 page.
Hodge, J.E., Chemistry of Browning Reactions in Model Systems, 1953, J. Agric. Food Chem., vol. 1, No. 15, pp. 928-943.
Agyei-Aye et al., “The Role of Anion in the Reaction of Reducing Sugars with Ammonium Salts,” Carbohydrate Research 2002, 337: 2273-2277.
Laroque et al., “Kinetic study on the Maillard reaction. Consideration of sugar reactivity,” Food Chemistry 2008, 111: 1032-1042.
Bjorksten et al., “Polyester Resin—Glass Fiber Laminates,” Industrial and Engineering Chemistry (1954).
Dow Corning, “A Guide to Silane Solutions,” 2005.
Knauf Data Sheet, 2006.
Molasses Corporation, United States Sugar Corporation, http://www.suga-lik.com/molasses/composition.html (Sep. 29, 2003).
Clamen, Guy, “Acrylic Thermosets: A Safe Alternative to Formaldehyde Resins,” Nonwovens World, Apr.-May 2004, pp. 96-102.
Opposition to AU 2006272595, Amended Statement of Grounds and Particulars, issued from Australian Patent Office, Jul. 6, 2012, 22 pages.
Decision re Opposition to AU 2006272595, issued from Australian Patent Office, Aug. 14, 2015, 25 pages.
Opposition to EP 1732968, Notice of Opposition: Prior Art, Scope of the Patent, Reasons for the Opposition, issued from European Patent Office, Mar. 8, 2012, 18 pages.
Decision re Opposition to EP 1732968, issued from the European Patent Office, Nov. 14, 2014, 5 pages.
Opposition to EA 019802, submitted to Eurasian Patent Office on Dec. 26, 2014, 36 pages.
Decision re Opposition to EA 019802, issued by Eurasian Patent Office on Aug. 18, 2015, 15 pages.
Owens Corning Retiree Update: What Goes Around, Comes Around: A tale of Natural Binders, revised Mar. 20, 2013, p. 4.
A.P. Bryant, “The Terminology of Sugars,” Industrial and Engineering Chemistry, vol. 26, No. 2, p. 231, Feb. 1934.
Food Flavor Chemistry, p. 162, Mar. 21, 2009 (English Abstract).
Mswanathan, T., “Chapter 28: Thermosetting Adhesive Resins from Whey and Whey Byproducts,” in Adhesives from Renewable Resources, ACS Symposium Series, Hemingway, R.W., et al. (Eds.), American Chemical Society, Washington, DC (1989).
Mswanathan, T., and Richardson, T., “Thermosetting Adhesive Resins from Whey and Whey Byproducts,” Ind. Eng. Chem. Prod. Res. Dev. 23:644-47, American Chemical Society, United States (1984).
Residential Energy Conservation: vol. 1, Congress of the U.S., Office of Technology Assessment (Ed.), 357 pages (Jan. 1, 1979).
Office action for co-pending U.S. Appl. No. 12/524,502 (9 pages)—Sep. 21, 2012.
Office action for co-pending U.S. Appl. No. 12/524,502 (9 pages)—Apr. 4, 2013.
Office action for co-pending U.S. Appl. No. 12/524,512 (7 pages)—Aug. 6, 2012.
Office action for co-pending U.S. Appl. No. 12/524,512 (9 pages)—Apr. 1, 2013.
Office action for co-pending U.S. Appl. No. 12/524,512 (14 pages)—Nov. 12, 2014.
Office action for co-pending U.S. Appl. No. 12/524,512 (9 pages)—Jul. 10, 2015.
Office action for co-pending U.S. Appl. No. 12/524,512 (10 pages)—Mar. 23, 2016.
Office action for co-pending U.S. Appl. No. 12/524,512 (13 pages)—Oct. 5, 2016.
Office action for co-pending U.S. Appl. No. 12/524,512 (13 pages)—Apr. 6, 2018.
Office action for co-pending U.S. Appl. No. 12/524,512 (15 pages)—Jan. 17, 2019.
Office action for co-pending U.S. Appl. No. 12/524,469 (7 pages)—Jun. 7, 2012.
Office action for co-pending U.S. Appl. No. 12/524,469 (8 pages)—Jan. 29, 2013.
Office action for co-pending U.S. Appl. No. 12/524,469 (7 pages)—Aug. 20, 2013.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—Jun. 9, 2014.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—Oct. 17, 2014.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—Jul. 23, 2015.
Office action for co-pending U.S. Appl. No. 12/524,539 (13 pages)—Jun. 21, 2012.
Office action for co-pending U.S. Appl. No. 12/524,539 (13 pages)—Jun. 6, 2013.
Office action for co-pending U.S. Appl. No. 12/524,539 (12 pages)—Dec. 17, 2014.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—Jul. 15, 2015.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—Mar. 23, 2016.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—Dec. 29, 2016.
Office action for co-pending U.S. Appl. No. 12/524,522 (4 pages)—Oct. 11, 2011.
Decision1 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (16 pages)—Jan. 4, 2016.
Decision2 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (19 pages)—Jan. 4, 2016.
Decision3 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (14 pages)—Jan. 4, 2016.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,926,464 (29 pages)—Oct. 2, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,464,207 (28 pages)—Oct. 2, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,469,747 (29 pages)—Oct. 3, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,828,287 (22 pages)—Oct. 16, 2018.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,828,287 (13 pages)—Jul. 17, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,464,207 (14 pages)—Jul. 31, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,926,464 (18 pages)—Aug. 5, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,940,089 (17 pages)—Oct. 16, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,039,827 (16 pages)—Oct. 16, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,469,747 (16 pages)—Nov. 9, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,464,207 (19 pages)—Aug. 27, 2021.
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,464,207 (14 pages)—Sep. 9, 2022.
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 9,464,207 (9 pages)—Jun. 8, 2023.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,926,464 (16 pages)—Sep. 7, 2021.
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,926,464 (15 pages)—Mar. 21, 2023.
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 9,926,464 (6 pages)—Jul. 25, 2023.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,469,747 (10 pages)—Sep. 16, 2021.
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,469,747 (9 pages)—Feb. 28, 2023.
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 9,469,747 (6 pages)—Jul. 25, 2023.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,114,210 (13 pages)—Dec. 1, 2021.
Office Action in Ex Parte Reexamination of U.S. Pat. No. 8,114,210 (11 pages)—Mar. 27, 2023.
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 8,114,210 (6 pages)—Aug. 8, 2023.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,940,089 (13 pages)—Jan. 28, 2022.
Office Action in Ex Parte Reexamination of U.S. Pat. No. 8,940,089 (11 pages)—Jul. 17, 2023.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,828,287 (11 pages)—Feb. 1, 2022.
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,828,287 (9 pages)—Feb. 28, 2023.
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 9,828,287 (6 pages)—Jul. 25, 2023.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,039,827 (13 pages)—Feb. 1, 2022.
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,039,827 (11 pages)—Aug. 16, 2023.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 8,114,210 (4 pages)—May 27, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,464,207 (4 pages)—Apr. 19, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,828,287 (5 pages)—May 5, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,926,464 (5 pages)—May 5, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,469,747 (8 pages)—May 21, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,039,827 (3 pages)—Jul. 2, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 8,940,089 (4 pages)—Jul. 13, 2021.
Petition for Post Grant Review of U.S. Pat. No. 10,968,629 (50 pages, filed Jan. 6, 2022 by Petitioner Rockwool International A/S).
Denial of Petition for Post Grant Review of U.S. Pat. No. 10,968,629 entered by Patent Trial and Appeal Board (19 pages)—Jul. 6, 2022.
Statement of Revocation Grounds re GB2496951—Claimant Rockwool International (May 21, 2018, 22 pages).
Statement of Revocation Grounds re GB2451719—Claimant Rockwool International (May 18, 2018, 22 pages).
Expert Report re Revocation of GB2451719 and GB2496951—Claimant Rockwool International (Nov. 12, 2018, 11 pages).
United Kingdom Intellectual Property Office, Decision in Rockwool International v. Knauf Insulation Limited, Application under Section 72 for revocation of patents GB2451719 and GB2496951 (May 28, 2019—18 pages).
Gogek Attorney Comments re U.S. Pat. No. 2,965,504—Apr. 6, 1960 (3 pages).
Gogek Affidavit Under Rule 132 re U.S. Pat. No. 2,965,504—Feb. 26, 1960 (3 pages).
Office action for co-pending U.S. Appl. No. 15/172,432 (16 pages)—Apr. 17, 2017.
Office action for co-pending U.S. Appl. No. 15/702,087 (5 pages)—Nov. 9, 2018.
Office action for co-pending U.S. Appl. No. 15/177,442 (17 pages)—May 19, 2017.
Office action for co-pending U.S. Appl. No. 15/378,159 (18 pages)—Mar. 2, 2017.
Office action for co-pending U.S. Appl. No. 15/222,122 (8 pages)—Nov. 20, 2017.
Office action for co-pending U.S. Appl. No. 15/310,837 (13 pages)—Jun. 21, 2018.
Office action for co-pending U.S. Appl. No. 15/411,972 (9 pages)—Mar. 28, 2017.
Office action for co-pending U.S. Appl. No. 15/411,972 (8 pages)—Nov. 29, 2017.
Office action for co-pending U.S. Appl. No. 15/411,972 (9 pages)—Jun. 14, 2018.
Office action for co-pending U.S. Appl. No. 15/116,254 (8 pages)—Apr. 26, 2018.
Office action for co-pending U.S. Appl. No. 15/116,254 (10 pages)—Aug. 15, 2018.
Office action for co-pending U.S. Appl. No. 15/116,254 (12 pages)—Nov. 3, 2021.
Office action for co-pending U.S. Appl. No. 15/333,670 (5 pages)—Dec. 8, 2017.
Office Action for co-pending U.S. Appl. No. 14/116,048 (10 pages)—Jun. 23, 2017.
Office action for co-pending U.S. Appl. No. 15/959,131 (8 pages)—Nov. 8, 2019.
Office action for co-pending U.S. Appl. No. 15/822,102 (6 pages)—Dec. 6, 2019.
Office action for co-pending U.S. Appl. No. 15/690,623 (7 pages)—May 24, 2019.
Office action for co-pending U.S. Appl. No. 15/690,623 (6 pages)—Jan. 9, 2020.
Office action for co-pending U.S. Appl. No. 16/357,320 (7 pages)—Jun. 10, 2021.
Office action for co-pending U.S. Appl. No. 16/357,320 (9 pages)—Dec. 29, 2021.
Office action for co-pending U.S. Appl. No. 16/357,320 (9 pages)—Apr. 14, 2022.
Other Information—Narrative of verbal disclosure of Brian Swift (1 page)—May 13, 2014.
Petition for Inter Partes Review of U.S. Pat. No. 8,114,210 (52 pages, filed Jun. 12, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,114,210 (58 pages, filed Jun. 12, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with Petition for Inter Partes Review of U.S. Pat. No. 8,114,210).
1st Petition for Inter Partes Review of U.S. Pat. No. D. 631,670 (68 pages, filed Jun. 19, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
2nd Petition for Inter Partes Review of U.S. Pat. No. D. 631,670 (62 pages, filed Nov. 2, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Decision of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. D. 631,670 (33 pages)—Jan. 12, 2016.
Decision2 of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. D. 631,670 (27 pages)—May 9, 2016.
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. D. 631,670 based on 1st Petition (56 pages)—Jan. 11, 2017.
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. D. 631,670 based on 2nd Petition (55 pages)—May 8, 2017.
Court of Appeals for Federal Circuit Judgment from Appeal of PTAB Decisions in Inter Partes Reviews of U.S. Pat. No. D. 631,670 (2 pages)—Jul. 13, 2018.
1st Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (61 pages, filed Jul. 1, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (70 pages, filed Jul. 1, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
2nd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (56 pages, filed Jul. 10, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (67 pages, filed Jul. 10, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 2nd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (62 pages, filed Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (76 pages, filed Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
Declaration of Dr. Elam Leed (11 pages, filed July 1, Jul. 10, and Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089, respectively).
Declaration of Dr. Jonathan Vickers (10 pages, filed July 1, Jul. 10, and Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089, respectively).
1st Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (60 pages, filed Jul. 29, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (72 pages, filed Jul. 29, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
2nd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (51 pages, filed Aug. 5, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (65 pages, filed Aug. 5, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 2nd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (57 pages, filed Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (75 pages, filed Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
Declaration of Dr. Elam Leed (11 pages, filed Jul. 29, August 5, and Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827, respectively).
Declaration of Dr. Jonathan Vickers (10 pages, filed Jul. 29, Aug. 5, and Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827, respectively).
Petition for Inter Partes Review of U.S. Pat. No. 9,469,747 (67 pages, filed Mar. 20, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,828,287 (86 pages, filed Mar. 23, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,464,207 (78 pages, filed Mar. 28, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,926,464 (74 pages, filed Mar. 30, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,888,445, mailed Dec. 24, 2013, in Control No. 90/013,029, 11 pages.
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,772,347, mailed Dec. 24, 2013, in Control No. 90/013,030, 14 pages.
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,854,980, mailed Apr. 15, 2014, in Control No. 90/013,156, 20 pages.
Declaration of Jan Rud Andersen submitted in Ex parte Reexamination Control No. 90/013,030, as Document OTH-C, Oct. 10, 2013, 4 pages.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (20 pages)—Jul. 24, 2015.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (23 pages)—Jul. 24, 2015.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (31 pages)—Aug. 18, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (4 pages)—Oct. 6, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (4 pages)—Oct. 6, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (4 pages)—Nov. 18, 2015.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (8 pages)—Mar. 23, 2016.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (8 pages)—Mar. 23, 2016.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (8 pages)—Mar. 22, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (17 pages)—Sep. 29, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (18 pages)—Sep. 29, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (22 pages)—Sep. 30, 2016.
Court of Appeals for Federal Circuit Judgment from Consolidated Appeal of PTAB Decisions in Ex Parte Reexamination of U.S. Pat. Nos. 7,888,445, 7,772,347 and 7,854,980 (5 pages)—Mar. 9, 2018.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,772,347 (4 pages)—Oct. 24, 2018.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,888,445 (4 pages)—Dec. 7, 2018.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,888,445 (14 pages)—Sep. 24, 2020.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,772,347 (13 pages)—Sep. 25, 2020.
Decision of USPTO to Reopen Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (7 pages)—Jan. 7, 2019.
Non-final Office Action from Reopened Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (26 pages)—Apr. 3, 2019.
Final Office Action from Reopened Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (11 pages)—Aug. 8, 2019.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,854,980 (3 pages)—Oct. 29, 2019.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,807,771 (4 pages)—Jan. 30, 2014.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,854,980 (6 pages)—Aug. 31, 2017.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (34 pages)—May 1, 2015.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (36 pages)—May 1, 2015.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,854,980 (25 pages)—Jul. 30, 2015.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (5 pages)—Dec. 9, 2015.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (5 pages)—Dec. 9, 2015.
Examiner's Determination on Patent Owner Response/Requester Comments after Board Decision in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (22 pages)—Oct. 17, 2016
Examiner's Determination on Patent Owner Response/Requester Comments after Board Decision in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (17 pages)—Oct. 17, 2016.
Court of Appeals for Federal Circuit Opinion/Judgment from Appeal of PTAB Decision in Inter Partes Reexamination of U.S. Pat. No. 7,854,980 (13 pages)—Feb. 27, 2017.
Final Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (25 pages)—Sep. 8, 2017.
Final Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (24 pages)—Sep. 8, 2017.
Decision of PTAB re Request for Rehearing in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (7 pages)—Feb. 12, 2018.
Decision of PTAB re Request for Rehearing in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (7 pages)—Feb. 12, 2018.
Court of Appeals for Federal Circuit Decision re Consolidated Appeal of PTAB Decision in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 and U.S. Pat. No. 7,888,445 (14 pages)—Oct. 15, 2019.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (3 pages)—Jul. 1, 2020.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (3 pages)—Jul. 1, 2020.
Decision of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. 8,114,210 (20 pages)—Oct. 21, 2015.
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. 8,114,210 (39 pages)—Oct. 19, 2016.
Court of Appeals for Federal Circuit Judgment from Appeal of PTAB Decision in Inter Partes Review of U.S. Pat. No. 8,114,210 (5 pages)—Jan. 16, 2018.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,114,210 (11 pages)—Apr. 9, 2020.
Decision1 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (16 pages)—Dec. 17, 2015.
Decision2 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (19 pages)—Dec. 17, 2015.
Decision3 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (14 pages)—Dec. 17, 2015.
U.S. Pat. No. 2,965,504—Part 1 (10 pages)—Dec. 20, 1960.
U.S. Pat. No. 2,965,504—Part 2 (14 pages)—Dec. 20, 1960.
U.S. Pat. No. 2,965,504—Part 3 (14 pages)—Dec. 20, 1960.
Related Publications (1)
Number Date Country
20220098452 A1 Mar 2022 US
Continuations (8)
Number Date Country
Parent 17386445 Jul 2021 US
Child 17498146 US
Parent 17323991 May 2021 US
Child 17386445 US
Parent 17194269 Mar 2021 US
Child 17323991 US
Parent 17129787 Dec 2020 US
Child 17194269 US
Parent 17063630 Oct 2020 US
Child 17129787 US
Parent 16941474 Jul 2020 US
Child 17063630 US
Parent 15931565 May 2020 US
Child 16941474 US
Parent 15326532 US
Child 15931565 US